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Abstract
Second generation antipsychotics (SGAs) are a key pharmacotherapy for the treatment of
schizophrenia but can cause serious metabolic side-effects, including obesity and type II diabetes
mellitus. Clinical studies have associated the high risk SGA olanzapine with hyperphagia,
increased abdominal adiposity, reduced physical activity and altered circulating metabolic
hormone levels, i.e. leptin, ghrelin and insulin; however, the underlying mechanisms remain
unclear. The hypothalamus and caudal brainstem are well-documented for their involvement in
appetite and energy homeostasis. Altered neurotransmission in these regions during olanzapine
treatment may contribute to metabolic dysfunction, however, the ability to examine drug effects
on neural signalling in humans in-vivo is limited. Therefore, an animal model is required that
mimics numerous aspects of clinical metabolic side-effects caused by olanzapine treatment.
Previous pre-clinical studies have utilised a range of olanzapine dosages and treatment regimes,
however the dose that best resembles the clinic is unclear.

Chapter 2 aimed to test the validity of the female rat model through its ability to mimic clinical
olanzapine-induced metabolic dysfunction. Female Sprague Dawley rats were treated orally,
three times daily with olanzapine (0.25mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0mg/kg), self-administered
in a sweet cookie dough pellet at 8-hourly intervals or vehicle (n=12/group) for 14-days. The
dosage response in each parameter was examined in order to identify the most appropriate dose
to use in the rat model. Olanzapine increased body weight (0.5, 1.0, and 2.0mg/kg olanzapine
treatment groups), food intake (2.0mg/kg olanzapine) and feeding efficiency (0.5-2.0mg/kg
olanzapine), but did not affect water intake. Subcutaneous inguinal (1.0-2.0mg/kg olanzapine)
and intra-abdominal perirenal fat were increased (2.0mg/kg), and a trend for an increase in
periovary fat mass was observed in the 2.0mg/kg olanzapine treatment group (p=0.07).
Interscapula brown adipose tissue mass was unchanged. Olanzapine decreased insulin in all
Katrina Green

xiii

dosage groups (0.25mg/kg-2.0mg/kg), increased circulating ghrelin and CCK, but had no effect
on peptide YY (3-36). Locomotor activity in the open field arena was reduced following olanzapine
treatment (0.5-2.0mg/kg olanzapine). Together, these findings demonstrate that multiple aspects
of clinically-reported metabolic side-effects associated with olanzapine treatment can be modelled
in the rat. In addition, this chapter demonstrated that low, clinically-relevant dosages of
olanzapine can cause metabolic effects when administered in-line with the half life of the drug
(i.e. 8-hourly). Therefore, this model is a valid foundation that can give insight into the in-vivo
effects of olanzapine on neurotransmission in the brain.

Following the demonstration in Chapter 2 of the metabolic side-effects of olanzapine, Chapters 3
and 4 aimed to elucidate the mechanisms underlying olanzapine-induced weight gain and insulin
dysregulation by examining the central in-vivo effects of olanzapine on key neurotransmitter
signals that regulate metabolic homeostasis in the hypothalamus and brainstem; including the
muscarinic, melanocortinergic, GABAergic and cannabinoid systems. In Chapter 3, the dosage
effects of olanzapine on muscarinic M3 receptor (M3R) binding density in the hypothalamic
arcuate (Arc) and ventromedial hypothalamic nucleus (VMH), and the dorsal vagal complex
(DVC) of the caudal brainstem were investigated, and relationships between changes in M3R
density and metabolic hormone levels were examined. Olanzapine increased M3R binding
density in the Arc and DVC (0.5-2.0mg/kg olanzapine), and the VMH (0.25-2.0mg/kg olanzapine),
and decreased blood glucose levels. Changes in M3R binding density significantly correlated with
plasma insulin, ghrelin and CCK, as well as food intake and body weight. Olanzapine is a potent
M3R antagonist, therefore the increase in M3R density was likely to be a compensatory
upregulation. Inhibition of the cholinergic pathway for insulin secretion by olanzapine’s M3R
blockade may explain the hypoinsulinaemia observed in treated rats, an effect that was
irrespective of dosage. The data shows that M3R blockade by olanzapine was also associated
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with altered levels of ghrelin and CCK. The results show for the first time that olanzapine acts on
M3Rs in regions of the brain that regulate appetite and insulin secretion, and support a role for
M3Rs in modulating insulin, ghrelin and CCK during olanzapine treatment, possibly via
cholinergic vagal innervation of the GI tract. This study provides a novel mechanism for
olanzapine’s diabetogenic and weight gain liability that can also apply independent of obesity; as
olanzapine can promote the onset of diabetes in normal-weight individuals in the clinic.

Several other key neurotransmitter systems involved in energy homeostasis may also play a role
in olanzapine-induced metabolic side-effects, including the potent orexigen neuropeptide Y (NPY)
and anorexigenic pro-opiomelanocortin (POMC) of the melanocortinergic system. The GABAergic
and endogenous cannabinoid systems are also documented for their effects on appetite and form
part of the hypothalamic microcircuitry that regulates POMC and NPY neurotransmission.
Chapter 4 revealed an olanzapine-induced increase in NPY (1.0-2.0mg/kg olanzapine) and
reduction in POMC mRNA expression (0.5-2.0mg/kg olanzapine) in the Arc but not in the DVC.
Cannabinoid CB1 receptor (CB1R) binding density decreased (Arc: 0.25-2.0mg/kg olanzapine,
DVC: 0.5-2.0mg/kg olanzapine) and GAD65 mRNA expression increased (Arc and DVC: 1.02.0mg/kg olanzapine) in both the Arc and DVC during olanzapine treatment. Taken together,
these results demonstrate that olanzapine alters the balance of major neuronal regulators of
energy homeostasis in a dose-sensitive manner that favours body weight gain. These data
provide evidence to support a novel mechanism for olanzapine-induced weight gain, whereby
increased NPY and enhanced inhibitory GABAergic output, through reduced CB1R density,
contribute to POMC inhibition.

Collectively, this thesis is novel in revealing that changes to major neurotransmission systems
involved in controlling energy homeostasis in the hypothalamus, and to a lesser extent, the
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brainstem, contribute to olanzapine-induced metabolic dysfunction. High expression of orexigenic
NPY and GABA, together with low expression of anorexigenic POMC and CB1R density may
favour positive energy balance during olanzapine treatment. The data also suggests that
blockade of the M3R in the hypothalamus and brainstem by olanzapine contributes to its
diabetogenic liability by causing insulin dysregulation, and to its weight gain risk by altering other
metabolic hormones including ghrelin and CCK levels, possibly via disruption to vagal cholinergic
innervation of the GI tract. Together, metabolic hormone imbalance, due to M3R antagonism by
olanzapine, may lead to alterations in neurotransmission through interactions between the braingut axis that regulates energy homeostasis. In addition, this thesis reveals that a dosage of
1.0mg/kg olanzapine (t.i.d.) is sufficient to induce changes in most parameters measured.
Overall, this thesis presents considerations for the discovery of new antipsychotic drugs with low
risk of metabolic side-effects and provides direction for the experimental design of future animal
modelling studies of antipsychotic effects.
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CHAPTER ONE
1.1. INTRODUCTION

Schizophrenia is a complex psychotic disorder that affects approximately 1% of the world’s
population and ranks within the top 10 causes of disability in developed countries world-wide.
Individuals with schizophrenia have a mortality rate 2.5 times higher than the general population,
and average life expectancy is reduced by approximately 10-years (Tandon et al., 2009).
Antipsychotic drugs are a key pharmacotherapy for the treatment of schizophrenia and a number
of other psychiatric illnesses. The newer ‘second generation’ antipsychotics (SGAs) are
prescribed to treat a range of symptoms and lack the debilitating extra-pyramidal and motor
dysfunction side-effects that are associated with older ‘first generation’ compounds. However,
SGAs can induce metabolic disturbances such as weight gain, abdominal adiposity,
dyslipidaemia, gluco-regulatory abnormalities and insulin-resistance (Newcomer, 2005), which
are particularly distinct in individuals treated with the high risk drugs, olanzapine and clozapine
(Allison et al., 2009; Newcomer, 2005). SGA-induced metabolic side-effects are of growing
concern due to associated co-morbidities such as obesity, type II diabetes mellitus and
cardiovascular disease. In addition, the incidence of diabetes and obesity in schizophrenia is 1.52.0 times higher than the general population (American Diabetes Association et al., 2004). These
factors, combined with increasing SGA prescription in both adults and children (Hollingworth et
al., 2010; Vitiello et al., 2009; Zuddas et al., 2011), highlight the urgency of the need to
understand the mechanisms underlying SGA-induced metabolic side-effects. Numerous
hypotheses have arisen over the past decade (Coccurello and Moles, 2010; Reynolds and Kirk,
2010), however, an indisputable answer has not yet been found. It is likely that a number of
metabolic facets interplay in the pathogenesis of SGA-induced metabolic side-effects, due to their
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broad receptor binding profile that allows multiple effects on central and peripheral cellular
pathways. In order to examine these side-effects in-vivo, there is a need for a valid and reliable
pre-clinical model of antipsychotic-induced metabolic dysfunction that closely resembles the
clinic. Therefore, the present PhD focused on the effects of olanzapine, a SGA with a high
metabolic liability, on key metabolic hormones and neurotransmitter systems in an animal model
of olanzapine treatment. Overall, this series of studies aimed to understand the mechanisms
underlying olanzapine-induced body weight gain and insulin dysfunction. A better understanding
of these mechanisms may assist the design of a new generation of antipsychotic drugs that
possess both therapeutic efficacy and reduced obesity / diabetes side-effects.

1.2. REVIEW OF LITERATURE
1.2.1 Schizophrenia

Schizophrenia is a mental disorder with diverse symptoms including retreat from reality, distorted
thoughts, cognitive and motor impairment, emotional dysfunction and a decline in communication
skills leading to social isolation, occupational disability and physical deterioration. Recent theory
suggests that schizophrenia is best described as a conglomeration of syndromes and diseases
rather than a single pathological state, due to the range of symptoms that can differ between
individuals (Tandon et al., 2009). Broadly, schizophrenia consists of three symptom domains:
positive, negative and cognitive. Positive symptoms include behavioural abnormalities such as
speech and thought disorder, delusions and hallucinations, while the negative domain
encompasses a decline in response such as flattened emotional expression, alogia, avolitionapathy and anhedonism (Andreasen et al., 1995; Tandon et al., 2009). Cognitive deficits include
reduced executive function such as organisation, memory and attention deficits, and altered
perception eg misinterpretation of behaviour and intent of others (Tandon et al., 2009).
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Several methods can be used to treat or attenuate the symptoms of schizophrenia, including
psychosocial rehabilitation and psychotherapy (Kern et al., 2009; Tandon et al., 2010); however
pharmacological intervention through the use of antipsychotic drugs remains a key component of
schizophrenia treatment. Unfortunately, the search for the perfect antipsychotic appears to be
frustrated by the complexity of the disease, as a percentage of patients remain unresponsive to
antipsychotic treatment (Meltzer, 1992; Suzuki et al., 2008). In addition, pharmacological therapy
for schizophrenia treatment involves a life-long adherence to drugs that are associated with an
array of side-effects (Anderman and Griffith, 1977; Bobes et al., 2003; Fakhoury et al., 2001;
Newcomer, 2005; Poyraz et al., 2008; Voruganti et al., 2000; Wirshing et al., 2002). Therefore,
despite robust improvements in psychopharmacological therapy over the past 60-years, more
research is required to aid discovery of highly efficacious drugs with low adverse side-effects.

1.2.2. Antipsychotic Drugs:

A History and Dichotomy of Generations

A. First Generation ‘Typical’ Antipsychotic Drugs
The early first generation or ‘typical’ antipsychotic compound, chlorpromazine, was discovered in
1950 by scientists at Rhone-Poulenc Laboratories (Paris, France) (reviewed in Newcomer, 2005;
Shen, 1999; Tandon et al., 2010). Chlorpromazine was initially observed to induce prolonged
sleep when administered with barbiturates and reduced the required dosage of anaesthetic
during medical surgery (Zirkle, 1973). A select group of psychiatrists were soon provided with the
drug and reported treatment success in patients exhibiting agitation, and hyperactive, erratic and
uncontrollable behaviour (reviewed in Shen, 1999). In 1952, Rhone-Poulenc Laboratories
released chlorpromazine as largactil, which was later remarketed as thorazine by Smith, Kline
and French (Philadelphia, PA). Thus began the era of first generation antipsychotic drug
development and a new hope for the selective treatment of schizophrenia. Chlorpromazine
remained a predominant prescription for schizophrenia until the 1970s, however many structurally
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similar typical antipsychotics were now available on the market, including haloperidol and
fluphenazine (López-Muñoz and Alamo, 2009; Millar, 1963). The discovery of haloperidol by
Janssen Pharmaceutica (Turnhout, Belgium) in 1958 also had an immense and long-term impact
on the ‘psychopharmacological revolution’. It later contributed to the first biologically-based
hypothesis on the etiopathology of schizophrenia by providing an experimental model to examine
the mechanisms of first generation antipsychotic drug efficacy in the treatment of schizophrenia
(reviewed in López-Muñoz and Alamo, 2009).

One of the earliest reports describing an effect of first generation antipsychotics on dopamine
neurotransmission dates back to 1963 (Carlsson and Lindqvist, 1963). Research has since
identified a correlation between clinical potency and antipsychotic drug binding affinity to the
dopamine D2 receptor sub-type, with an occupancy of between 60 – 80% of D2 receptors in the
brain inducing a therapeutic response (Kapur, 1998). However, at these levels, D2 receptor
antagonism can cause serious motor and extrapyramidal side-effects (EPS) such as tremor,
akinesia, slurred speech, tardive dyskinesia and Parkinsonism (Farde et al., 1992). In fact, the
link between EPS and an antipsychotic drug’s efficacy in treating what was then thought of as
schizophrenia in its entirety, was solidified with the introduction of haloperidol and first reports of
this correlation date back to 1959 (Hippius, 1989; Shen, 1999). However, it is now generally
accepted that first generation antipsychotic drugs have preferential therapeutic effects on the
positive symptoms of schizophrenia, which are largely caused by dopaminergic dysregulation in
the mesolimbic and mesocortical pathways in the brain (Howes and Kapur, 2009; Tost et al.,
2010), but have less therapeutic benefit for the negative and cognitive domains of the disease
(Kapur and Remington, 2001). A significant portion of the schizophrenia population is
unresponsive to D2 receptor antagonists (Meltzer, 1992), which suggests that D2 blockade alone
is insufficient to treat schizophrenia in all cases. Wolkin et al., (1989) found that individuals with
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antipsychotic-resistant schizophrenia had the same central uptake of a D2 antagonist ([18F]Nmethylspiroperidol) as antipsychotic-responsive patients following treatment with the typical
antipsychotic haloperidol, indicating that the absence of antipsychotic effect in non-responsive
schizophrenia was not due to altered D2 receptor binding or drug uptake. Thus, a need was
identified for a new line of pharmacological therapeutics that had a broader neurotransmitter
receptor binding profile and greater efficacy in treating the positive, negative and cognitive
domains of schizophrenia, while addressing the important issue of EPS.

B. Second Generation ‘Atypical’ Antipsychotic Drugs
In the early 1960s, scientists from Wander Pharmaceuticals (Bern, Switzerland) developed
clozapine, an antipsychotic drug with a reduced risk of EPS (Breier et al., 1994; Shen, 1994).
Clozapine was effective in treating both the positive and negative symptoms of schizophrenia
(Breier et al., 1994) and was efficacious in treating a percentage of individuals that were
previously antipsychotic-unresponsive (Kane et al., 1988). However, it was rapidly removed from
the market upon reports from Finland that its use was associated with fatal agranulocytosis, an
acute and severe lowering of the granulocyte class of white blood cells (Idänpään-Heikkilä et al.,
1977). Despite this set-back, excitement over its success in treating previously non-responsive
schizophrenia was maintained by a few scientists at Sandoz Laboratories (Switzerland), who had
purchased the original developers of the drug, Wander Pharmaceuticals (Shen, 1999). Later, a
large-scale, double-blind study by Kane and colleagues (1988) reported clozapine’s efficacy and
safety in treating non-responsive schizophrenia when individuals were monitored for blood
abnormalities, assisting the launch of clozapine onto the USA market in 1990 (Shen, 1999).

Thus began the rapid development of a new ‘second generation’ of antipsychotic drugs, including
olanzapine, clozapine, risperidone, quetiapine and ziprasidone, that were reportedly effective at
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treating multiple domains of schizophrenia and showed reduced risk of EPS (Newcomer, 2005). A
clear dichotomy had now formed between the older first generation ‘typical’ and newer second
generation ‘atypical’ antipsychotic drugs. A precise definition of ‘atypicality’ that allows infallible
categorisation of all antipsychotic drugs remains elusive. However, atypical antipsychotic drugs
are those that generally possess a profile to affect a range of receptors, notably adrenergic α1
and α2, histaminergic H1, muscarinic M1 and serotonergic 5-HT1A, 5-HT2A and 5-HT2C, with less
preference to dopamine D2 receptor binding and therefore a lower propensity to cause EPS than
first generation drugs (Reynolds, 1998; Richelson and Souder, 2000; Roth et al., 2004) Table
1.1). The recent introduction of aripiprazole adds to the difficulty in differentiating typical from
atypical antipsychotics: it acts largely on the dopamine D2 receptor (similar to first generation
typical antipsychotic drugs) but has a low risk of inducing EPS, can treat multiple symptoms of
schizophrenia (similar to second generation atypical antipsychotics) and has a low metabolic
liability (Naber and Lambert, 2004). Several studies suggest that aripiprazole is a ‘functionally
selective’ antipsychotic drug that may cause different cell signalling cascades through the one
receptor sub-type, i.e. an agonist of one pathway and antagonist of another (Mailman and Murthy,
2010; Urban et al., 2006). Aripiprazole may achieve its therapeutic efficacy with reduced sideeffects by causing differential actions on the dopamine D2 receptor (Mailman and Murthy, 2010)
in different pathways in the brain (Han et al., 2009). Therefore, aripiprazole may have a different
mode of action to other antipsychotic drugs and could be considered a new class of antipsychotic
drug – a third generation antipsychotic (Mailman and Murthy, 2010),

The efficacy of second generation antipsychotics to treat the positive, negative and cognitive
symptoms of schizophrenia may be related to their broad receptor binding profile (Reynolds,
1998) (Table 1.1). However, drug effects on multiple neural and peripheral pathways may also
underlie the numerous adverse side-effects associated with their use (Nasrallah, 2008). Metabolic
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Table 1.1: Receptor binding affinities of selected antipsychotic drugs (Ki nM)
Receptor binding affinity (Ki nM) for some common typical and atypical antipsychotics, including first#, second## and third### generation drugs.
Ki determinations were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract # HHSN-271-200800025-C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie
Driscol at NIMH, Bethesda MD, USA. *Kroeze et al., (2003), **Richelson and Souder (2000), ***Silvestre and Prous (2005)
Receptor

CHLOR#

HAL#

CLOZ##

OLAN##

RISP##

QUET##

ZIPR##

ARI###

D1
D2
5-HT1A
5-HT2A
5-HT2C
α1
α2
H1
M1
M3
CB1

112
2
3115
1.8
25
2.6
769.23
6*
47
47
>10000

83
2
1202
61**
4700**
17**
600**
3002
>10000
>10000
>10000

189
431
105
2.59**
4.8**
6.8**
15**
2
14
25
>10000

58
72
610**
1.48**
4.1**
44**
280**
4.9
24
51
>10000

60
4.9
190**
0.15**
32**
2.7**
8**
5.18
>10000
>10000
>10000

712
567
431
31**
3500**
8.1**
80**
7.5
858
1943
>10000

30
4
1.9**
0.12**
0.9**
2.6**
154**
130
>10000
>10000
>10000

387
0.95
5.6
8.7*
22.4*
30***
70***
29
6776
4677
>10000

Antipsychotic drug: CHLOR: chlorpromazine, HAL: haloperidol, CLOZ: clozapine, OLAN: olanzapine, RISP: risperidone, QUET: quetiapine, ZIPR: ziprasidone,
ARI: aripiprazole.
Receptors: D1: dopamine1, D2: dopamine2, 5-HT1A: serotonin1A, 5-HT2A: serotonin2A, 5-HT2C: serotonin2C, α1: adrenergic1, α2: adrenergic2, H1: histamine1, M1:
muscarinic1, M3: muscarinic3, CB1: cannabinoid1
Katrina Green

7

side-effects such as weight gain, abdominal adiposity, dyslipidaemia, gluco-regulatory
abnormalities and insulin-resistance, are commonly observed during SGA treatment (Allison et
al., 2009; Newcomer, 2005) and are of growing concern due to associated co-morbidities, such
as obesity, type II diabetes mellitus and cardiovascular disease, and the increasing popularity of
this drug class (Centorrino et al., 2002; Hollingworth et al., 2010; Vitiello et al., 2009; Zuddas et
al., 2011). Unfortunately, people with schizophrenia have a 1.5-2.0 times higher incidence of
obesity and type II diabetes mellitus than the general population (American Diabetes Association
et al., 2004) and weight gain is an important contributing factor to medication non-compliance
(Weiden et al., 2004). These critical issues highlight the importance and urgency of
understanding the mechanisms underlying antipsychotic-induced metabolic side-effects.

The SGA olanzapine is commonly used in the clinical setting due to its efficacy to treat the
multiple domains of schizophrenia, its tolerability and low patient discontinuation rate (Haro et al.,
2009; Lieberman et al., 2005). In addition, wide-spread prescription for bipolar disorder, major
depression, dementia, Alzheimer’s disease, anorexia nervosa and Tourette’s syndrome has been
reported in adults and children (Ballard et al., 2006; Brambilla et al., 2007; Bridle et al., 2004;
Budman et al., 2001; Centorrino et al., 2002; De Hert et al., 2011; Frenchman, 2005; Zuddas et
al., 2011). However, with the exception of clozapine, olanzapine has the highest weight gain and
diabetogenic liability of all other antipsychotic drugs (Allison et al., 2009; Newcomer, 2005;
Silvestre and Prous, 2005). A study by Zipursky et al., (2005) found that individuals treated with
olanzapine at the normal dosage range of 5-20mg/day gained 9.2kg within the first 12 weeks of
therapy, increasing to 15.5kg after 52 weeks and plateauing at 15.4kg after 2 years. Another
study reported a mean estimated body weight gain of 4.45kg and 4.15kg following 10-weeks
clozapine and olanzapine treatment, respectively (Allison et al., 1999). Chronic olanzapine
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treatment is also associated with hyperinsulinaemia, hepatic insulin-resistance and type II
diabetes mellitus (Oriot et al., 2008; Perez-Iglesias et al., 2008). Even short-term (2-weeks)
olanzapine treatment can induce insulin dysregulation in individuals with schizophrenia (Chiu et
al., 2010). Some potential mechanisms of SGA-induced metabolic dysfunction have emerged in
the past few years, including from our laboratory (Deng et al., 2010; Deng et al., 2007b; Han et
al., 2008a; Huang et al., 2006a; Huang et al., 2006b; Weston-Green et al., 2008) and others (see
reviews by Coccurello and Moles, 2010; and Reynolds and Kirk, 2010). However, an indisputable
hypothesis remains elusive, perhaps because antipsychotic drugs differ markedly in their
pharmacological profiles, and because of the complex and well-preserved interactions between
the systems involved in energy homeostasis. Olanzapine may interfere in a number of signalling
pathways to cause metabolic abnormalities. Therefore, investigation into drug effects on key
regulators of energy homeostasis in regions of the brain involved in metabolic control is crucial in
order to better understand the mechanisms underlying these metabolic side-effects.

1.2.3 The Control of Energy Homeostasis

I am hungry, therefore I eat. This seemingly simple concept is the outside mask of an elaborate
and complex web of well-preserved interactions between multiple neural and peripheral networks
that signal through a swarm of hormones, peptides and neurotransmitters to integrate information
about energy stores and requirements in order to maintain energy homeostasis. This section of
the review will focus on some promising targets that may assist in understanding the mechanisms
of antipsychotic drug-induced metabolic dysfunction.

A. Metabolic Hormonal Signals and the Effect of Antipsychotic Drugs
Appetite and satiety signals, such as orexigenic ghrelin and anorexigenic insulin, CCK and PYY,
are secreted on a meal-to-meal basis to signal the body’s acute energy requirements, whereas
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leptin is secreted from adipocytes in direct proportion to fat mass and signals the long-term
energy stores of the body to the brain (Orr and Davy, 2005). Metabolic hormones exert their
effects primarily on the hypothalamus and caudal brainstem to promote or suppress feeding
behaviour. Hormonal imbalances and/or resistance are associated with obesity and diabetes
(Schwartz and Porte, 2005; Wren and Bloom, 2007). Antipsychotic drugs may influence these
hormonal signals and their pathways in the brain to induce metabolic side-effects.

I. Insulin
Insulin lowers glucose levels broadly through two mechanisms: facilitating glucose uptake and
suppressing hepatic glucose production (Bouche et al., 2004). Insulin is secreted from pancreatic
β-cells during two phases of digestion: the cephalic phase (i.e. anticipatory) in order to prime the
body for glucose absorption, and the gastric phase (i.e. post-absorptive) in response to increasing
blood glucose levels (Ahrén, 2000) (discussed further on page 23). Insulin facilitates glucose
uptake into gluco-responsive tissues, such as the liver and skeletal muscle, and maintains blood
glucose homeostasis. It also acts on various regions of the brain, particularly the hypothalamus
and brainstem, which are abundant in insulin receptors (Pardini et al., 2006; Unger et al., 1991).
Insulin can inhibit food intake, in part, by suppressing expression of the potent orexigen,
neuropeptide Y (NPY) (Schwartz et al., 1992). It is commonly classified as an adiposity signal,
along-side leptin, as insulin levels in the absence of glucose stimulation are proportional to
adiposity (Baskin et al., 1999; Polonsky et al., 1988; Schwartz et al., 2000).

Studies have shown that insulin is excessively elevated following food intake in human obesity
and remains elevated post-prandially past 2 hours, unlike lean subjects whose insulin levels
return to basal readings after 2 hours (Polonsky et al., 1988; Zwirska-Korczala et al., 2007).
Chronically elevated insulin levels and concurrent hyperglycaemia may be indicative of insulinKatrina Green
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resistance, and are characteristic symptoms of type II diabetes mellitus (Ahrén, 2000). In addition,
the link between obesity and insulin-resistance is well-documented (Belfiore and Iannello, 1998;
Goossens, 2008), although insulin–resistance and diabetes can also occur independent of
excessive body weight (Arner et al., 1991).

Chronic olanzapine treatment increases plasma insulin and induces insulin-resistance in humans
(Oriot et al., 2008; Perez-Iglesias et al., 2008; Sacher et al., 2008; Wu et al., 2008), rats (Albaugh
et al., 2006), and mice (Coccurello et al., 2009), while restoration of normal glycaemic control has
been reported following discontinuation of antipsychotic administration (Koller et al., 2001). Even
a single acute dose of olanzapine, risperidone or clozapine can cause hyperglycaemia and
hyperinsulinaemia, impair insulin-sensitivity, and induce insulin-resistance (Boyda et al., 2010b;
Houseknecht et al., 2006). Reports also show that olanzapine treatment can decrease glucosestimulated insulin levels in the clinic following short-term (14-days) olanzapine treatment (Chiu et
al., 2006), and in male rats following a single acute dose of olanzapine (Chintoh et al., 2008a).
Olanzapine and clozapine, both with a high diabetogenic liability, can directly decrease insulin
secretion from pancreatic β cells in-vitro, whereas ziprasidone and risperidone, SGAs with a
lower risk of inducing type II diabetes mellitus, have no effect on insulin secretion (Johnson et al.,
2005). The ability of clozapine and olanzapine to decrease insulin secretion in the short-term may
be related to their receptor binding profile, for example both drugs are potent antagonists of the
cholinergic muscarinic M3 receptor (M3R) (Bymaster et al., 1999; Johnson et al., 2005), which
facilitates insulin production and secretion from pancreatic β cells (Johnson et al., 2005; Ruiz de
Azua et al., 2011). Therefore, direct blockade of the M3R by olanzapine may interfere in insulin
levels in the body. Further review of the M3R and its potential role in olanzapine-induced insulin
dysregulation is detailed on pages 26 and 27.
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II. Ghrelin
Ghrelin is a hunger hormone primarily released from endocrine cells in the stomach to stimulate
feeding. In addition to the stomach, ghrelin has been detected in a number of other tissues such
as the pancreas and brain, albeit at lower levels (Hou et al., 2006; van der Lely et al., 2004).
Ghrelin exerts its orexigenic effects through the growth hormone secretagogue receptor (GHS-R)
(Cowley et al., 2003; Kojima et al., 1999; Kojima and Kangawa, 2005). It enters the brain and acts
on regions such as the hypothalamus and brainstem to promote food intake (Cone et al., 2001).
Circulating ghrelin peaks immediately prior to a meal, then decreases rapidly post-prandially
(Tschop et al., 2001). Peripheral ghrelin administration induces food intake in humans (Wren et
al., 2001), and central and peripheral administration promotes food intake, weight gain and
adiposity in rats (Wren et al., 2000). Fasting plasma ghrelin concentrations are reduced in human
obesity compared to lean controls (Shiiya et al., 2002; Tschop et al., 2001; Zwirska-Korczala et
al., 2007), indicating a possible compensatory down-regulation of the orexigenic hormone during
a chronic positive energy state.

The reported effects of atypical antipsychotic drugs on circulating ghrelin levels are inconsistent
(Atmaca et al., 2007; Esen-Danaci et al., 2008; Kluge et al., 2009; Tanaka et al., 2008), (also see
Jin et al., 2008 for review). For example, studies have shown that treatment with olanzapine,
clozapine and risperidone significantly elevates fasting bioactive ghrelin (n-octanoylated ghrelin)
levels in humans and rats (Esen-Danaci et al., 2008; Murashita et al., 2007; Murashita et al.,
2005). The finding that ghrelin is increased following SGA treatment coincides neatly with the
elevated risk of weight gain side-effects of these drugs and suggests dysfunction of central
feedback mechanisms or over-secretion of the hormone that induces hyperphagia. Jin and
colleagues (2008) compiled the results of 8 studies on ghrelin following SGA treatment in humans
and found that 3 studies reported an increase in ghrelin, 2 reported a decrease, while 3 studies
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showed no change in circulating ghrelin levels. There is a need to investigate the effects of SGAs
on ghrelin using an appropriate animal model that eliminates some of the variables associated
with human studies, such as drug dosage, treatment duration, concomitant treatments, starting
BMI, age and family history (Gebhardt et al., 2009).

III. Cholecystokinin (CCK)
CCK is an anorectic hormone that is predominantly secreted by endocrine I cells in the mucosa of
the duodenum, jejunum and proximal ileum of the upper intestine in response to amino and fatty
acid absorption through the intestinal mucosal wall (Buchan et al., 1978). It signals the body’s
satiated state to the brain by binding to receptor sub-types 1 and 2 (CCK1R and CCK2R, formerly
CCK-A and CCK-B) on vagal nerve afferents that project to the brainstem (Dockray, 2009), and
through CCK-2R receptors in the hypothalamus (Orr and Davy, 2005). CCK can also influence
food intake by directly acting on the myenteric plexus (Cooper et al., 2008b). CCK signalling is
altered in clinical obesity and in obese animal models, i.e. fasting and postprandial CCK levels
decreased in morbidly obese women compared to lean controls (Zwirska-Korczala et al., 2007),
and were reduced in the hypothalamus of mice fed a high-fat diet for 10 weeks (Morris et al.,
2007). In addition, peripheral administration of CCK decreases meal size and frequency in
humans, rats and mice (Geary, 2004; Gutzwiller et al., 2000; Lieverse et al., 1995), and plays an
important role in stimulating pancreatic secretion (Konturek et al., 2003)

Reports on the effects of antipsychotics on CCK levels are limited. Vidarsdottir et al. (2010) found
a slight pre-prandial morning increase in plasma CCK levels in healthy male olanzapine-treated
subjects, and an association between polymorphisms in the CCK2R receptor and antipsychoticinduced weight gain has been suggested (Tiwari et al., 2010a). However, the effects of
antipsychotic drugs on circulating CCK in an animal model of metabolic dysfunction are unknown.
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IV. Peptide Tyrosine Tyrosine (PYY)
PYY is referred to as the ‘ileal brake’ on food intake and is released by endocrine cells in the
ileum in response to fatty acids present in the intestine (Chaudhri et al., 2005). PYY(3-36), an
endogenous form of PYY, has a high affinity for appetite-influencing NPY Y1 and Y5 receptors,
and binds irreversibly to Y2 receptors (Batterham and Bloom, 2003; Dautzenberg and Neysari,
2005). The hypothalamus and brainstem express NPY receptors and may play a role in mediating
the anorexigenic effects of PYY (Fetissov et al., 2004). In particular, the caudal brainstem has a
high density of Y2 receptors in the brain (Dumont et al., 1996). Fasting and postprandial plasma
PYY levels are reduced in human obesity (Batterham et al., 2003; Zwirska-Korczala et al., 2007)
and peripheral PYY administration can attenuate food intake by approximately 30% in both lean
and obese humans (Batterham et al., 2003). Taken together, these findings illustrate a role for
PYY in the pathogenesis of obesity, and highlight its potential candidature for obesity
therapeutics, as humans do not appear to be resistant to its satiating effects (Batterham et al.,
2003).

Olanzapine treatment alters PYY binding in regions in the brain, including the medial amygdaloid
nucleus, medial geniculate nucleus and superficial gray layer of the superior colliculus,
parabrachial pigmented nucleus and periaqueductal gray (Wang and Huang, 2008). Vidarsdottir
et al. (2010) reported no change in circulating PYY levels in healthy olanzapine-treated male
subjects. However, the effects of olanzapine on PYY in an animal model of antipsychotic-induced
metabolic dysfunction have not been reported.
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V. Leptin
Leptin is predominantly expressed in adipocytes by the ob gene and circulating leptin levels
parallel adiposity. Leptin enters the brain to act on regions such as the hypothalamus and
brainstem to reduce food intake (Vong et al., 2011), though a reduction in leptin can signal
depleted energy storage and induce hyperphagia (Zhang et al., 1994). Exogenous application of
leptin results in hypophagia and weight loss, as well as increased energy expenditure in mice
(Zhang et al., 1994). Mutated leptin signalling, i.e. obese (ob/ob) mice that lack a functional leptin
gene and diabetic (db/db) mice that lack leptin receptors, results in an obese phenotype, while
the application of recombinant leptin to leptin-mutant strains induces weight loss (Geary, 2004;
Halaas et al., 1995; Pelleymounter et al., 1995), identifying leptin as an important regulator of
body weight. These finding that leptin could reduce body weight initially sparked excitement for
the possible therapeutic benefits of leptin treatment for human obesity (Friedman and Halaas,
1998). However, excitement was soon quelled by the observation that morbidly obese human
subjects had high plasma leptin concentrations, despite high body mass index (BMI), and some
were unresponsive to exogenous leptin administration (Heymsfield et al., 1999). It is now
generally accepted that obesity is a condition of leptin-resistance rather than deficiency, due to
the failure of leptin to activate key satiety signalling pathways and attenuate body weight gain in
clinical obesity, despite chronically high levels of the hormone (Caro et al., 1996; Heymsfield et
al., 1999; Maffei et al., 1995; Morrison, 2008).

As with ghrelin, studies on the effects of atypical antipsychotics on fasting plasma leptin levels
appear to be conflicting. For example, Jin and colleagues (2008) reviewed 30 papers dated
between 1998 and 2007 and found that most studies agreed on a SGA-induced increase in
circulating leptin, which commonly correlated to BMI or body fat mass. However, 11 papers
revealed no change in leptin, particularly when data was adjusted for BMI, while 1 showed a
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decrease (Jin et al., 2008). Confounding factors such as body mass index at the time of testing,
antipsychotic dosage, length of treatment, concomitant treatments, treatment history and history
of illness may contribute to this contrast in results (Gebhardt et al., 2009).

As leptin is secreted by adipocytes to signal the quantity of fat stores, it has been proposed that
hyperleptinaemia during antipsychotic treatment may be reflective of weight gain/adiposity and
not a direct drug action (Jin et al., 2008). However, several studies indicate that olanzapine may
directly increase fat reserves, for example, olanzapine induces adipogenesis in-vitro through
enhanced expression of sterol regulatory element-binding protein 1, which together with its
related genes promotes the production of adipocytes (Yang et al., 2007). Olanzapine also
enhances differentiation of pre-adipocytes to mature adipocytes and triglyceride accumulation invitro (Yang et al., 2007). In male rates, olanzapine enhances fuel uptake in adipocytes and
attenuates lipolysis (Albaugh et al., 2010).

B. The Brain-Gut Axis
If you’ve ever felt a sudden pang of hunger after looking at an appetising meal, you know that the
stomach listens attentively to the brain. Likewise, when you are full, food seems less appetising
as the brain begins to listen to the stomach. The digestive system closely interacts with the brain
in a well-preserved bi-directional manner to convey multitudes of chemical and electrical
messages pertaining to energy stores, nutritional value of incoming food, mechanical distension,
hunger and satiety. This system is referred to as the brain-gut axis (Figure 1.1). The hypothalamic
arcuate nucleus (Arc) and the dorsal vagal complex (DVC) of the caudal brainstem form
important components of the brain-gut axis by integrating information from peripheral metabolic
hormonal signals originating from the gastrointestinal (GI) tract and adipocytes, as well as
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Figure 1.1: Schematic of the Brain-Gut Axis.
Food intake decreases orexigenic ghrelin from the stomach and increases anorexigenic
hormones such as cholecystokinin (CCK) and peptide YY(3-36) (PYY(3-36)) from the upper intestine.
Glucose is absorbed into the blood stream and stimulates pancreatic release of insulin, which
acts to restore normal glycaemic levels by promoting glucose uptake and inhibiting food intake.
During periods of high energy intake leptin is released from adipocytes to signal enhanced fat
mass. These signals converge on neurons of the hypothalamus and the dorsal vagal complex of
the caudal brainstem to convey information pertaining to the body’s acute and long-term
nutritional status. During periods of low energy the brain stimulates feeding behaviour that is
associated with an increase in ghrelin and reduced levels of insulin, CCK, PYY(3-36) and leptin.
This feedback mechanism acts to maintain energy homeostasis, and dysfunction of the brain-gut
axis can result in a shift in energy balance associated with obesity or anorectic eating disorders.
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neurotransmitter signalling from other brain regions, resulting in the overall stimulation or
inhibition of food intake (Berthoud, 2002; Orr and Davy, 2005). Peripheral hormones can signal to
the brain by either passing through the blood-brain barrier to their respective neuronal receptors,
or by acting on receptors expressed on vagal afferent fibres from the GI tract to the brain
(reviewed in Dockray, 2009). Thus, the hypothalamus and brainstem represent parallel systems
for integrating neural and peripheral information crucial for maintaining energy homeostasis, and
manipulation of metabolic signals and their receptors in these regions may be prime targets for
the prevention or treatment of antipsychotic-induced metabolic dysfunction.

C. The Neural Control of Appetite and Glucose Homeostasis
The neural control of appetite involves integration of multiple pathways in the brain including
those pertaining to the metabolic, emotional, cognitive, memory, sensory and anticipatory/reward
motivators of feeding behaviour. Thus, the desire to eat, or lack thereof, engages most regions of
the brain, from the brainstem through to the hippocampus and cortex (Shin et al., 2009; Stice et
al., 2009). The hypothalamus and the caudal brainstem are well-recognised as key regions
facilitating energy homeostasis, integrating and responding to metabolic hormone signals based
on the body’s acute and long-term energy stores and requirements (Berthoud, 2002; Broberger
and Hökfelt, 2001).

I. The Role of the Hypothalamus and Caudal Brainstem in Energy Homeostasis
Classic studies identified the ventromedial hypothalamic (VMH) nucleus as the ‘satiety centre’,
while the lateral hypothalamic area (LHA) was deemed the ‘hunger centre’ (reviewed in Bray et
al., 1990; Stellar, 1954), however the theory of a single appetite centre has since been expanded
(Shin et al., 2009). The hypothalamic Arc is an important modulator of energy homeostasis and
may influence both sides of the energy equation: food intake and physical activity (Coppari et al.,
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2005). The Arc is a circumventricular organ that is situated adjacent to the third ventricle and
projects through the overlying permeable medial eminence, allowing circulatory sampling via
access to the portal vascular system and cerebrospinal fluid, in order to integrate and respond to
peripheral metabolic hormonal signals (Cone et al., 2001; Peruzzo et al., 2000). The Arc also
receives information from an abundance of intrahypothalamic connections, including from the
lamina terminalis and the subfornical organ located in the anterior hypothalamus, which carry
information about olfactory, visual, taste and reward aspects of feeding (Berthoud, 2002; Wuchert
et al., 2009). In addition, the Arc also projects to other brain regions important in the regulation of
energy homeostasis, including the VMH (Chee et al., 2010), and the dorsal vagal complex (DVC)
of the caudal brainstem (Berthoud, 2008; Broberger and Hökfelt, 2001; Gray et al., 1986; Hou et
al., 2006).

The DVC, comprised of the dorsal motor nucleus (DMN), nucleus of the solitary tract (NTS) and
the area postrema (AP), can respond to circulating metabolic hormones through the permeable
AP that borders the fourth ventricle (Wuchert et al., 2009). In addition, projections between the
Arc, DVC and the vagus nerve allow direct regulation of gastrointestinal function and feeding
(Berthoud, 2008; Gray et al., 1986; Hou et al., 2006; Tebbe et al., 2001; Travagli et al., 2006;
Zheng et al., 2005). Furthermore, vagal afferents from the alimentary canal provide rapid
information to the brainstem and hypothalamus pertaining to the nutritional value of food in the GI
tract, circulating and stored fuel status, mechanical GI signals such as gastric distension, as well
as the regulation of circulating metabolic hormones including insulin, ghrelin and CCK (Berthoud,
2008; Gray et al., 1986; Tebbe et al., 2001). The DVC receives gastrointestinal afferent fibres that
travel to the brain via the vagus nerve, medulla and solitary tract to terminate on neuronal cell
bodies and dendrites of the NTS (Rogers et al., 1996; Travagli et al., 2006). NTS inter-neurons
then project to the efferent vagal preganglionic neurons of the DMN, which descend and synapse
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on intra-ganglionic fibres of the abdominal viscera (Rogers et al., 1996; Travagli et al., 2006).
Signalling between NTS afferents and DMN efferents is dynamic and sensitive to influences such
as hormones, neurotransmitters and synaptic signalling from other brain regions, including the
hypothalamus (Gray et al., 1986; Hou et al., 2006; Travagli et al., 2006). Altered efferent output
can have potent effects on the modulation of gastrointestinal function and energy homeostasis
(Gray et al., 1986; Hou et al., 2006; Travagli et al., 2006), for example, high densities of postganglionic fibres originating from the DMN terminate in the stomach and alterations in DMN
signalling can influence gastric motility, which effects glycaemia and insulin levels by altering the
absorption rate of glucose (reviewed in Berthoud et al., 1991; Gilon and Henquin, 2001; Okumura
and Namiki, 1990; Travagli et al., 2006).

Pro-opiomelanocortin (POMC) and Neuropeptide Y (NPY)
The hypothalamic Arc contains two distinct ‘first-order’ neuronal populations: a mediallypositioned group of orexigenic neurons co-expressing NPY and agouti-related protein (AgRP),
and an opposing anorexigenic cluster co-expressing pro-opiomelanocortin (POMC) and cocaineand amphetamine-regulated transcript (CART) localised in the lateral part of the Arc. POMC and
NPY mRNA are also expressed in the DVC (Bronstein et al., 1992; Wai et al., 2004), and NPY
mRNA expression has been reported in the VMH (Huang et al., 2006b). The POMC gene
encodes for neuropeptides such as β-endorphin, adrenocorticotropic hormone and αmelanocortin stimulating hormone (α-MSH); the latter exerts its anorexigenic effects largely
through melanocortin MC-3 and MC-4 receptor (MC4-R) subtypes. Conversely, the central
application of NPY induces food intake in a number of species and chronic over-exposure to NPY
leads to obesity in rats (Beck et al., 1992; Stanley et al., 1986), while NPY inhibition can attenuate
feeding and body weight (reviewed in Minor et al., 2009). NPY exerts its effects through G-protein
coupled NPY receptors, termed Y1-5, located throughout the brain including the hypothalamus
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and brainstem (Dumont et al., 1996; Fetissov et al., 2004). NPY Y1,2,4 and Y5 receptors are
implicated in the regulation of food intake (Abbott et al., 2005; Kalra and Kalra, 2003; Yahya et
al., 2006). Genetic animal models of hyperphagia and obesity, such as Zucker fatty rats (fa/fa),
obese (ob/ob) and diabetic (db/db) mice, exhibit enhanced hypothalamic NPY and reduced
POMC mRNA expression (Beck et al., 1993; Kim et al., 2000; reviewed in Minor et al., 2009).
NPY/AgRP neurons release gamma-aminobutyric acid (GABA), the primary inhibitory
neurotransmitter in the central nervous system, from axonal terminals that synapse on POMC
neurons in order to stimulate feeding behaviour (Cone et al., 2001). In the Arc, POMC neurons
are also inhibited by local non-NPY/AgRP GABAergic neurons but are disinhibited by the
application of leptin, which acts directly on these newly characterized presynaptic GABAergic
neurons to suppress inhibitory tone to POMC (Vong et al., 2011). Indeed, the appetite enhancing
effects of hypothalamic GABA were reported more than 30 years ago (Meeker and Myers, 1980),
however, to-date, there has been minimal research into the underlying mechanisms (Wu and
Palmiter, 2011). NPY and POMC neurons are sensitive targets for a number of peripheral
metabolic hormones including leptin, insulin, ghrelin, CCK and PYY (Cone et al., 2001; Meister,
2007; Valassi et al., 2008; van den Top et al., 2004), allowing response to the acute nutritional
status of the body and the long-term regulation of energy stores. For example, activation of
ghrelin receptors expressed on NPY neurons stimulates inhibitory GABA release onto POMC
neurons to promote appetite (Cone et al., 2001), whereas leptin depolarizes and increases the
firing rate of POMC neurons while reducing NPY-mediated GABAergic inhibition of POMC
(Cowley et al., 2001; van den Top et al., 2004). NPY also has a robust effect on locomotor activity
as studies have shown that intracerebroventricular administration of NPY in rats significantly
attenuates home cage activity and open-field locomotion in a reversible manner (Heilig and
Murison, 1987; Heilig et al., 1988). Other authors have also reported altered locomotor activity
following intervention into NPY signalling by pharmacological and genetic manipulation (Costoli et
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al., 2005; Edelsbrunner et al., 2009a; Edelsbrunner et al., 2009b; Heilig et al., 1989; Karl et al.,
2008; Maric et al., 2009; Pedrazzini et al., 1998). In particular, the Arc, which houses a large
quantity of NPY neurons, has been identified as target for leptin-mediated locomotor regulation
(Coppari et al., 2005). Taken together, the literature has revealed an important role for the Arc
and DVC as a target site for numerous satiety and hunger signals, and an integral modulator of
appetite. NPY and POMC neurons can regulate energy homeostasis through opposing influences
on appetite and, in-part, physical activity. Therefore, antipsychotic drug effects on NPY or POMC
expression may cause a significant shift in energy balance that favours body weight gain. POMC
genetic variations have been described as a susceptibility for antipsychotic-induced body weight
gain (Correll and Malhotra, 2004). However, investigation into the effects of antipsychotic drugs
on NPY or POMC signalling in the hypothalamus and brainstem is limited.

II. The Central Control of Insulin Secretion and Glucose Homeostasis
The maintenance of glucose levels tightly within the normal range of 4.5 and 6mM involves a fine
balance of physiological, cellular and molecular alterations (Ahrén, 2000; Gilon and Henquin,
2001). A number of reviews have highlighted the role of the brain in glucose homeostasis and
insulin secretion (Bereiter et al., 1981; Burcelin, 2010; Kalra, 2008; Konturek et al., 2003;
Schwartz and Porte, 2005; Thorens, 2010; Woods et al., 1985). Indeed, the influence of the CNS
on insulin secretion was recognised by Pavlov as early as 1910 (Pavlov, 1941). Other classical
studies identified glucose-stimulated hyperinsulinaemia following VMH lesioning (Frohman et al.,
1969; Hales and Kennedy, 1964; Rohner-Jeanrenaud and Jeanrenaud, 1980) that was reversed
immediately following bilateral sub-diaphragmatic vagotomy (Bereiter et al., 1981; Berthoud and
Jeanrenaud, 1979). Collectively, these studies indicated a regulatory role for the hypothalamus in
insulin secretion via the vagus nerve. More recently, early neuronal activity (via c-fos expression)
has been detected in the Arc, VMH and paraventricular nucleus (PVN) following an acute
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intracarotid injection of glucose at a concentration insufficient to increase peripheral glucose
levels (Guillod-Maximin et al., 2004), and c-fos expression was detected in neurons of the DMN
and NTS of the DVC following insulin-induced hypoglycaemia (Yuan and Yang, 2002). These
findings show that specific brain regions are activated in response to glucose levels, in particular,
select nuclei of the hypothalamus and brainstem. In fact, emerging theory suggests that diabetes
is a disease of the central nervous system as alterations in hypothalamic and brainstem signalling
promote abnormal glucose metabolism and insulin function characteristic of insulin-resistance
and type II diabetes mellitus (Elmquist and Marcus, 2003; Obici et al., 2003; Obici et al., 2002;
Schwartz, 2001). Therefore, these regions are of interest in the pathogenesis of antipsychoticinduced insulin dysfunction and type II diabetes mellitus side-effects.

The Cephalic and Gastric Phases of Insulin Secretion
Insulin is secreted in response to two phases of digestion: the cephalic phase, which occurs prior
to nutrient absorption based on sensory input to the brain in anticipation of feeding, and the
gastric phase that occurs in response to nutrient absorption from food present in the GI tract. The
cephalic phase of insulin secretion is largely reliant on sensory (i.e. visual and olfactory) and
oropharyngeal innervation via cranial nerves derived from the brainstem (Ahrén, 2000; Gilon and
Henquin, 2001). It acts to prime the body for glucose absorption by preparing the liver, muscles
and adipose tissue for glucose uptake. It may also function to reduce the post-prandial load on
pancreatic β-cells (Gilon and Henquin, 2001). Diabetes is associated with impaired cephalic
phase response, which contributes to hyperglycaemia due to improper nutrient detection
(Burcelin, 2010; Knauf et al., 2008). The cephalic insulin response is partially regulated by vagal
cholinergic mechanisms, as response is suppressed by vagotomy and the application of atropine,
a muscarinic receptor antagonist (Gilon and Henquin, 2001). Conversely, the gastric phase of
insulin secretion occurs when absorbed glucose present in the hepatic portal vein activates
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enteric glucose sensors that enhance vagal firing to the brain (Gilon and Henquin, 2001; Knauf et
al., 2008; Thorens, 2010). The NTS, Arc and VMH contain early response neurons to intragastric
glucose infusion (detected via c-Fos expression) (Knauf et al., 2008), and efferent pathways
derived from the hypothalamus and brainstem mediate an increase in vagal efferent nerve firing
to the pancreas during insulin-induced hypoglycaemia (Wu et al., 2004). Taken together, these
studies indicate an important role for the hypothalamus and brainstem in both the cephalic and
absorptive phases of insulin secretion that involves cholinergic vagal innervation of the pancreas.

III. Neurotransmitter Signalling Pathways in Metabolism
As discussed above, the DVC and hypothalamus play important roles in regulating energy
homeostasis, therefore, neurotransmission within these regions is of interest in the
pathophysiology underlying antipsychotic-induced metabolic side-effects. A number of
neurotransmitter systems are associated with food intake and body weight regulation, including
noradrenergic, serotonergic, dopaminergic and histaminergic signalling pathways (Meister, 2007).
The endogenous cannabinoid system is also well-documented concerning its regulatory role in
energy homeostasis (Bermudez-Silva et al., 2010; Li et al., 2011; O'Hare et al., 2011) and we
previously reported that olanzapine induced a robust decrease in cannabinoid receptor binding
density in the DVC that correlated to body weight gain (Weston-Green et al., 2008). Furthermore,
the muscarinic signalling pathway can regulate metabolic hormones through cholinergic-mediated
vagal innervation of the gastrointestinal tract (Lee et al., 2002; Liddle, 2000) and is a key
modulator of pancreatic insulin production and secretion (Ruiz de Azua et al., 2011). Therefore,
the cannabinoid and muscarinic signalling pathways are prime candidates in the pathogenesis of
antipsychotic-induced obesity and diabetes side-effects.
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a. Cholinergic Muscarinic Neurotransmission: Role in Glucose and Energy
Homeostasis, and Antipsychotic-Induced Metabolic Dysfunction
Acetylcholine (ACh) is an important neurotransmitter of the central and peripheral nervous system
and exerts its effects through ionotropic nicotinic and metabotropic muscarinic receptors. Plasma
membrane-bound muscarinic ACh receptors are widely expressed throughout the brain and
periphery, with dominant expression in the parasympathetic nervous system. Five muscarinic
receptor genes have been classified to-date, denoted M1-M5 (Caulfield and Birdsall, 1998).
Muscarinic receptors have a number of roles in the gastrointestinal tract, including secretory, i.e.
insulin and gastric acid secretion, and smooth muscle contraction, for example regulation of
gastric motility and peristalsis (Ochi et al., 2005; Ruiz de Azua et al., 2011; Travagli et al., 2006).
ACh has been identified in the hypothalamus and brainstem, for example more than 95% of DMN
neurons are immunoreactive for choline acetyl-transferase, the ACh-synthesising enzyme
(Armstrong et al., 1990; Travagli et al., 2006). ACh is also present in the Arc and overlying
median eminence, and choline acetyl-transferase and vesicular ACh transporter immunoreactivity
has been reported in POMC neurons of the Arc (Meister et al., 2006; Walaas and Fonnum, 1978).
Given the role of the hypothalamus and brainstem in appetite and gastrointestinal function via the
vagus nerve, cholinergic neurotransmission in these regions may be implicated in the metabolic
abnormalities observed during SGA treatment through drug interactions with muscarinic
receptors.
i. Parasympathetic and Sympathetic Regulation of Insulin Secretion
Parasympathetic and sympathetic regulation of pancreatic secretion plays a major role in glucose
homeostasis. Sympathetic innervation inhibits insulin secretion from pancreatic islet β-cells during
periods of hypoglycaemia and stimulates α-cells to release glucagon (partly mediated by ACh)
(Ahrén, 2000). Glucagon promotes the conversion of stored glycogen in the liver to glucose,
which is released into the circulation. Conversely, parasympathetic vagal activation stimulates
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insulin secretion from β-cells in the pancreas. Parasympathetic pre-ganglionic fibres arise largely
in the DMN of the DVC, descend via the hepatic and gastric branches of the vagus nerve to enter
the pancreas along the pancreatic vessels and terminate at the intra-pancreatic ganglia dispersed
throughout the exocrine pancreas (Ahrén, 2000; Buijs et al., 2001). Post-ganglionic nerve fibres
arising from the intrapancreatic ganglia penetrate the pancreatic islets and terminate proximal to
the endocrine cells (Ahrén, 2000; Gilon and Henquin, 2001). Vagal nerve stimulation causes the
preganglionic nerve terminal to release ACh, which activates nicotinic receptors expressed on the
intraganglionic neuron (Ahrén, 2000; Gilon and Henquin, 2001). Activation of the post-ganglionic
fibres causes the release of several neurotransmitters, including ACh, pituitary adenylate cyclase
activating polypeptide, vasoactive intestinal polypeptide and gastrin-releasing peptide, that bind to
their respective receptors expressed on β-cells to influence insulin production and secretion
(Ahrén, 2000; Ruiz de Azua et al., 2011).

ii. The Muscarinic M3 Receptor
The M3R is a G protein-coupled receptor (GPCR) belonging to the Gq/11-coupled receptor subfamily (Ahren, 2009). It is abundantly expressed by pancreatic β-cells and activates the glucosestimulated ACh pathway for insulin secretion through two second messenger cascade systems,
diacylglycerol and inositol 1,4,5-trisphosphate (Ahrén, 2000). The M3R pathway for AChmediated insulin secretion in the β-cell is reviewed in Ruiz de Azua et al. (2011). The
physiological importance of the cholinergic M3R in energy balance is evidenced in genetic
mutational studies where M3R-deficient mice exhibit a lean phenotype, are hypophagic,
hypoglycaemic, hypoinsulinaemic, and have reduced glucagon levels (Duttaroy et al., 2004;
Yamada et al., 2001; Zawalich et al., 2004). Although glucose metabolism is unaltered in
hepatocyte-specific M3R-deficient mice (Li et al., 2009), mice selectively deficient in M3R
expressed on pancreatic β-cells exhibit decreased serum insulin levels and impaired glucose
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tolerance compared to their wide-type littermates (Gautam et al., 2006b). In stark contrast,
transgenic mice that selectively over-express M3Rs specifically on pancreatic β-cells exhibit a 3
fold increase in insulin secretion accompanied by a 35% decrease in blood glucose levels during
fasted and fed states compared to wildtypes (Gautam et al., 2010). In addition, M3Rs are widely
expressed throughout the brain, including the VMH, Arc and DVC (Levey et al., 1994; Zubieta
and Frey, 1993). Several studies have shown a dynamic sensitivity of central M3Rs to the
glucometabolic state of the body, for example increased M3R density has been reported in the
brainstem of hyperglycaemic streptozotocin-induced diabetic rats (Balakrishnan et al., 2009),
M3R expression is increased in the brainstem of hyperinsulinaemic normoglycaemic rats
following a partial pancreatectomy (Renuka et al., 2004), and changes in M3R binding sensitivity
in response to glycaemia have been reported in the cerebellum (Antony et al., 2010). Taken
together, these findings demonstrate a critical role for cholinergic M3Rs in maintaining glycaemic
balance and highlight central M3Rs as promising targets in the mechanisms of SGA-induced type
II diabetes mellitus and obesity.

iii. M3 Receptor Role in Antipsychotic-Induced Metabolic Dysfunction
Accumulating evidence over the past decade has shown a role for the muscarinic M1, M2 and M4
receptor sub-types in the pathology of schizophrenia (Dean et al., 2004; Deng and Huang, 2005;
Raedler et al., 2007; Scarr et al., 2009) and antipsychotic drug efficacy (Deng et al., 2007b; Scarr
and Dean, 2009). However, the M3R does not appear to be involved in the pathology of
schizophrenia (Scarr et al., 2006) or the therapeutic effects of antipsychotics (Bymaster and
Felder, 2002). Instead, antipsychotic binding affinity to the M3R is thought to be related to its
metabolic side-effects (Coccurello and Moles, 2010; Jindal and Keshavan, 2006; Johnson et al.,
2005; O'Neill, 2005; Reynolds and Kirk, 2010; Starrenburg and Bogers, 2009). Indeed, a number
of factors may contribute to antipsychotic-induced diabetes and obesity side-effects (reviewed in
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Coccurello and Moles, 2010; Reynolds and Kirk, 2010; Starrenburg and Bogers, 2009). However,
M3R binding affinity has been identified as a predictor of antipsychotic diabetogenic liability
(Silvestre and Prous, 2005) and relates, in part, to weight gain risk (Matsui-Sakata et al., 2005).
Interestingly, olanzapine and clozapine, antipsychotic drugs with high diabetogenic and
obesogenic liabilities, have a receptor binding profile to potently block the M3R, while low-risk
antipsychotics, such as risperidone and ziprasidone, have little effect on the M3R (Johnson et al.,
2005) (Table 1.1). Coinciding with their relative risk for diabetes side-effects, olanzapine and
clozapine decrease glucose and carbachol (a muscarinic receptor agonist) -stimulated insulin
from pancreatic β-cells, whereas risperidone and ziprasidone have no effect on insulin secretion
in-vitro (Johnson et al., 2005). This finding suggests that olanzapine and clozapine can impair the
cholinergic pathway for insulin secretion by blocking the M3R (Figure 1.2).

In the clinic, chronic olanzapine treatment is associated with hyperinsulinaemia, hepatic insulin
resistance and type II diabetes mellitus (Oriot et al., 2008; Perez-Iglesias et al., 2008), which can
also be modelled pre-clinically (Albaugh et al., 2006; Chintoh et al., 2008b; Coccurello et al.,
2009). However, a growing body of evidence suggests that short-term/acute olanzapine and
clozapine treatment decreases fasting plasma insulin levels and attenuates glucose-stimulated
insulin response (Chintoh et al., 2008a; Chiu et al., 2010; Chiu et al., 2006; Johnson et al., 2005;
Oriot et al., 2008). Importantly, a recent report by Chiu et al (2010) noted a time-dependent
change in glucose-stimulated insulin response in individuals with schizophrenia, whereby insulin
levels decreased during the first two weeks of olanzapine treatment compared to their base-line
levels, returned to base-line levels after 4-weeks treatment, and increased following 8-weeks
olanzapine treatment. It is possible that direct blockade of the M3R during the initial olanzapine
treatment period (2-weeks) causes a decrease in glucose-stimulated insulin secretion, which
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Figure 1.2: Potential Mechanism for the Involvement of Muscarinic M3
Receptors (M3Rs) in Olanzapine-Induced Metabolic Dysfunction
(1) Activation of the M3R in the hypothalamus and brainstem stimulates acetylcholine (ACh)
release from the parasympathetic vagal efferent terminal (2). ACh activates M3Rs expressed on
pancreatic β-cells (3) to facilitate the production and secretion of insulin (4). However, olanzapine
is a potent M3R antagonist and blockade of the M3R may inhibit the cholinergic pathway for
insulin secretion, resulting in hypoinsulinaemia following short-term treatment. M3R density may
increase in response to M3R antagonism in an attempt to maintain homeostasis. This may cause
a rise in insulin levels over time that precedes insulin-resistance and type II diabetes mellitus
commonly observed in the clinic following chronic olanzapine treatment. (5) Olanzapine’s
blockade of M3R-mediated vagal-cholinergic innervation of the GI tract may also contribute, inpart, to its weight gain liability by altering the levels and action of other metabolic hormones, such
as ghrelin (6) and CCK (7), in a manner that contributes to positive energy balance.
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may result in a compensatory increase in insulin response in the long-term. In other words, M3R
antagonism by olanzapine may disrupt the ACh-pathway for insulin secretion that precedes
insulin-resistance and type II diabetes mellitus.

Olanzapine’s antagonism of the M3R may also contribute to the pathogenesis of obesity through
interference in the ACh-mediated regulation of gastrointestinal function, including secretion of
hormones such as ghrelin and CCK, via vagal innervation to the stomach and intestines. For
example, parasympathetic activity is low during periods of fasting to promote the gastric secretion
of ghrelin (Lee et al., 2002). Ghrelin is tonically inhibited by the vagus nerve and truncal vagotomy
results in an increase in circulating ghrelin levels, suggesting a cholinergic mechanism involving
the DVC in the regulation of ghrelin secretion (Lee et al., 2002). ACh is the predominant
excitatory neurotransmitter released from post-ganglionic terminals impinging on the GI tract
(Travagli et al., 2006). In addition, CCK secretion and satiating effects are influenced by vagalcholinergic mechanisms (Liddle, 2000; Smith et al., 1981). Efferent preganglionic fibres originate
in the DMN and afferent fibres from the GI tract feed into the DMN via the NTS. This vagal
circuitry is sensitive to neurotransmitter signalling and input from other brain regions such as the
hypothalamus. Therefore, direct drug antagonism of cholinergic receptors, for example the M3R,
in these regions may impair metabolic signalling leading to an imbalance in energy homeostasis
(Figure 1.2). However, the effects of olanzapine on M3Rs in regions of the brain that regulate
insulin secretion and GI function are unknown.
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b. Cannabinoid System: Role in Food Intake and Antipsychotic-Induced Weight
Gain
The appetite enhancing effects of cannabis sativa (marijuana) were observed by Indian
mendicants and utilised for the treatment of weight loss as far back as 300AD (Abel, 1975).
Cannabinoids exert their effects through metabotropic Gαi/o-coupled receptors, termed CB1
(CB1R) and CB2 (CB2R). Cannabinoid receptors (CBRs) are expressed in areas such as the
brain, pancreas, adipose tissue and skeletal muscle (Nogueiras et al., 2009) and on vagal
afferent fibres innervating the GI tract (Burdyga et al., 2004; Harrold and Williams, 2003). The
expression of CB1Rs in the brain is wide-spread, including the hypothalamus and particularly
strong expression in the DVC (Glass et al., 1997; Van Sickle et al., 2003). Cannabinoid CB2Rs
were initially thought to be confined to the peripheral immune system (Munro et al., 1993;
Pertwee, 1997), however, later studies reported weak CB2R expression in the DVC (Van Sickle
et al., 2005) and CB2R immunoreactivity in other brain regions (Gong et al., 2006).

Endogenous cannabinoids are important modulators of neural processes including cognition,
neurodevelopment and central cardiovascular control (Bermudez-Silva et al., 2010). The
cannabinoid system is also well-recognised for its influence on appetite. For example, exogenous
cannabinoids, such as delta(9)-tetrahydrocannabinol (Δ9-THC, the main psychoactive component
of marijuana) and CBR agonist, CP-55,940, increase food intake in rats and mice (Cota et al.,
2003a; Miller et al., 2004; Wiley et al., 2005). In addition, endogenous cannabinoids, anandamide
and 2-arachidonoyl glycerol (2-AG), promote re-feeding in satiated rats (Kirkham et al., 2002;
Williams and Kirkham, 1999) and levels are increased in animal models of obesity, including
obese db/db and ob/ob mice, and fatty Zucker rats (Di Marzo et al., 2001). The potential for the
endocannabinoid system to modulate metabolism is vast, including central and peripheral
implications in appetite, hedonic reward and addiction aspects of feeding, glucose and lipid
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metabolism, and energy expenditure (Cavuoto and Wittert, 2009; Harrold and Williams, 2003;
Nogueiras et al., 2009). The hyperphagic effects of cannabinoids are thought to be mediated by
the CB1R, for example, genetic CB1R-deficient mice are lean and hypophagic compared to their
wild-type littermates (Cota et al., 2003b; Di Marzo et al., 2001; Wiley et al., 2005), and CB1R
blockade by SR141716A (rimonabant hydrochloride) inhibits the hyperphagic effects of 2-AG,
anandamide, CP-55,940 and Δ9-THC in rats and mice (Bermudez-Silva et al., 2010; Li et al.,
2011). In fact, SR141716A was approved as a prescription drug for the treatment of human
obesity in 2006, marketed as Acomplia® (Sanofi-Aventis, Paris, France), with reports of weight
loss ranging from 5-10% of the initial body weight after 1 year of treatment (Van Gaal et al.,
2005). However, it was suspended from the market in 2008 (Sanofi-Aventis press statement,
Paris, November 5, 2008) following reports of serious adverse side-effects such as
gastrointestinal dysfunction, mood disorder, depression and suicide (reviewed in Bermudez-Silva
et al., 2010; Li et al., 2011; Van Gaal et al., 2005). SR141716A is a CB1R inverse agonist (i.e. it
blocks potential agonist binding and inhibits receptor constitutive activation), however CB1R
antagonism (i.e. partial or complete blockade of potential agonist binding) is still considered a
viable potential pharmacological strategy against human obesity (Bermudez-Silva et al., 2010).

Endogenous cannabinoids are also important modulators of normal neuronal transmission. Unlike
classical neurotransmitters, endocannabinoids can function as retrograde synaptic inhibitors of
neuronal signalling (Alger, 2002) (Figure 1.3). They are released from the post-synaptic neuron
and diffuse retrogradely across synapses to activate CB1Rs expressed on the presynaptic
terminal. Upon activation, pre-synaptic CB1Rs suppress neurotransmitter release through a
number of mechanisms, including inhibition of voltage-activated Ca2+ channels by the CB1R Gprotein βγ-subunits, which suppresses vesicular neurotransmitter release (Alger, 2002).
Retrograde synaptic inhibition by the cannabinoid system has been reported in a number of brain
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Figure 1.3: Schematic of Cannabinoid-Mediated Retrograde Transmission
(1) Endogenous cannabinoids are released from the post-synaptic cell either under basal
conditions or following post-synaptic depolarisation. (2) Cannabinoids diffuse in a retrograde
manner across the synaptic cleft and activate G protein-coupled cannabinoid CB1 receptors
(CB1Rs) expressed by the pre-synaptic neuron or interneuron. (3) Activation of the CB1R
releases the CB1R G protein-coupled βγ sub-unit, which inhibits opening of the Ca2+ channel
and influx of Ca2+. (4) A reduction in Ca2+ decreases the probability of synaptic vesicle
movement to the pre-synaptic cleft and subsequent release of the neurotransmitter onto the postsynaptic neuron.
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regions, such as the hippocampus, striatum, cortex, and nucleus accumbens (Fukudome et al.,
2004; Istvan et al., 1999; Kawamura et al., 2006; Narushima et al., 2006; Ohno-Shosaku et al.,
2002; Sperlágh et al., 2009; Uchigashima et al., 2007; Urbanski et al., 2010), as well as the
hypothalamus and DVC (Derbenev et al., 2004; Hentges et al., 2005; Ho et al., 2007; Nguyen
and Wagner, 2007).

In the hypothalamus, POMC neurons of the Arc continuously express endocannabinoids under
basal conditions that can activate CB1Rs on GABA interneurons and suppress GABA release
(Hentges et al., 2005). In addition, Ho et al. (2007) reported a reduction in glutamatergic
excitation of POMC by exogenous application of CB1R agonist, WIN 55,212-2, and an increase in
glutamate firing on POMC following CB1R antagonism by AM251. These studies suggest a role
for the cannabinoid system in regulating POMC activity in the hypothalamic Arc. As previously
mentioned, the POMC gene is also expressed by neurons of the DVC (Bronstein et al., 1992),
and CB1R-mediated retrograde inhibition of GABAergic and glutamatergic neurotransmission has
been reported in the DVC. For example, Derbenev et al. (2004) reported presynaptic CB1Rmediated suppression of inhibitory and excitatory input to the DMN. They identified a number of
DMN neurons as gastric-related, suggesting that cannabinoid signalling in the DVC may influence
gastrointestinal function (Derbenev et al., 2004). Taken together, it is possible that interference in
the normal signalling of the cannabinoid system may influence body weight as a result of altered
GABAergic / glutamatergic input to POMC neurons in the hypothalamus and brainstem. Indeed,
GABA is the predominant inhibitory neurotransmitter of the central nervous system and a role for
GABAergic signalling in appetite regulation has been reported, i.e. hypothalamic GABA is
increased in fasted rats during feeding (Meeker and Myers, 1980) and GABA is co-localised with
both NPY and POMC neurons in the Arc (Meister, 2007). In addition, messenger RNA (mRNA)
for glutamic acid decarboxylase (GAD) isoforms GAD65 and GAD67 (the rate limiting enzyme for
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GABA synthesis), the vesicular GABA transporter and GABA transporter 1 proteins have been
detected in the Arc and DVC (Meister, 2007; Stornetta and Guyenet, 1999; Yasumi et al., 1997).
Anorexigenic PYY(3-36) decreases GABA release on POMC neurons (Batterham et al., 2002), and
GABA mediates NPY tonic inhibition of POMC in the Arc (Cowley et al., 2001). Therefore, it is
possible that GABAergic signalling in the hypothalamus may be involved in antipsychotic-induced
weight gain side-effects.

i. Cannabinoid Neurotransmission and Antipsychotic Drugs: Role in
Metabolic Dysfunction
We have previously shown that olanzapine treatment induces a robust decrease in [3H] CP55,940 binding density in the DVC of rats, whereas low metabolic-risk antipsychotics, aripiprazole
and haloperidol, have little or no effect (Weston-Green et al., 2008). In addition, we observed a
strong positive correlation between [3H] CP-55,940 binding density and body weight gain
following chronic olanzapine treatment (Weston-Green et al., 2008). An olanzapine-induced
decrease in CBR binding density during body weight gain does not appear to fit with the
documented appetite and body weight suppressive effects of CB1R blockade (Li et al., 2011).
However, interference in cannabinoid signalling by olanzapine may affect anorexigenic POMC
and contribute to body weight gain side-effects. As mentioned in the section above, endogenous
cannabinoids released from POMC neurons in the Arc activate CB1Rs expressed on GABA
neurons and can suppress GABAergic inhibition of the post-synaptic POMC neuron (Hentges et
al., 2005; Ho et al., 2007; Nguyen and Wagner, 2007). Reduced GABA may disinhibit POMC and
promote hypophagia (Ho et al., 2007). A reduction in CB1R binding density following olanzapine
treatment may decrease CB1R-mediated suppression of GABA, reinstating GABAergic inhibition
of POMC. Therefore, it is possible that olanzapine-induced weight gain side-effects occur, in part,
through reduced anorexigenic POMC expression in the Arc and DVC as a result of decreased
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CB1R-mediated retrograde inhibition of GABA. However, the effects of olanzapine on CB1R in
the hypothalamus are unknown, and olanzapine’s influence on POMC and GABA expression in
these regions is unclear. In addition, the ligand used in our earlier study, CP-55,940, has a high
affinity for the CB1R, but also binds at a low level to the CB2R (Pertwee, 1997), therefore,
whether the decrease in CBR binding density observed in the DVC following olanzapine
treatment could be attributed to the CB1R requires clarification.

1.2.4 Animal Model of

Antipsychotic-Induced Weight Gain

Clearly there are many questions about the mechanisms by which SGAs alter appetite and body
weight regulation. However, the ability to investigate antipsychotic effects in humans in-vivo,
particularly in the brain, is limited for obvious technological and ethical reasons. An appropriate
animal model that closely mimics the human scenario is required in order to examine the central
mechanisms of antipsychotic-induced metabolic dysfunction. For the past decade scientists have
worked to establish an animal model that mimics human antipsychotic-induced metabolic sideeffects. However, reports are varied possibly due to differences in experimental parameters such
as drug selection, dosage, and method of drug administration, treatment duration and interval,
and strain and gender of animal. The experimental parameters and outcomes of a large number
of animal modelling studies of antipsychotic-induced metabolic dysfunction were recently
reviewed (Boyda et al., 2010a; Coccurello and Moles, 2010).

A. Antipsychotic Drug Selection, Dosage Regime and Administration Method
Although clinical data indicates clozapine has the highest metabolic liability of all antipsychotic
drugs (Allison et al., 1999; Newcomer, 2005), reports to-date have shown limited success in
modelling clozapine-induced obesity side-effects in the rat or mouse (Choi et al., 2007;
Coccurello and Moles, 2010; Cooper et al., 2008a). In fact, clozapine treatment can even reduce
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body weight in the rat (Cooper et al., 2008a). This failure to induce weight gain or hyperphagia in
rats treated with clozapine may be due to sedation that interferes with eating behaviour (Albaugh
et al., 2006; Cooper et al., 2008a). Some studies have been able to replicate certain aspects of
clinically-reported metabolic side-effects in the rat using clozapine, for example, hypergylcaemia,
hyperinsulinaemia, impaired insulin sensitivity and induced insulin-resistance (Boyda et al.,
2010b; Houseknecht et al., 2006; Murashita et al., 2007; Smith et al., 2008; Tulipano et al., 2007),
enhanced fat intake (Hartfield et al., 2003), increased ghrelin and adiponectin levels (Cooper et
al., 2008a; Murashita et al., 2007), and enhanced adipose accumulation; though the latter had no
effect on overall body weight (Cooper et al., 2008a). Other studies have reported on the effects of
risperidone, quetiapine, ziprasidone and sulpiride on metabolic parameters in rats and mice with
varied outcomes (Baptista et al., 2002; Boyda et al., 2010a; reviewed in Coccurello and Moles,
2010; Cope et al., 2009; Ota et al., 2002; Savoy et al., 2008; Smith et al., 2008), though these
drugs have a lower clinical metabolic risk than olanzapine and clozapine (Allison et al., 1999;
Newcomer, 2005).

Multiple aspects of clinically-reported metabolic side-effects following olanzapine treatment have
been modelled in rats and mice, including body weight gain, hyperphagia, adiposity,
hypolocomotor activity, hyperglycaemia, hyperinsulinaemia, insulin-resistance, and circulating
metabolic hormone imbalances (Albaugh et al., 2010; Baptista et al., 2007; Beebe et al., 2006;
Boyda et al., 2010b; Chintoh et al., 2009; Chintoh et al., 2008a; Coccurello et al., 2009;
Coccurello et al., 2008; Cooper et al., 2008a; Huang et al., 2006b; Lee and Clifton, 2002;
Lykkegaard et al., 2008; Park et al., 2010; Shobo et al., 2010; van der Zwaal et al., 2010), (also
see Coccurello and Moles, 2010 for review). However, animal modelling studies differ in
numerous experimental design parameters, including dosage. For example, olanzapine increased
food intake, weight gain, adiposity and induces insulin-resistance in female Han-Wistar, Hooded-
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Lister and Sprague Dawley (SD) rats at dosages ranging from 0.5 – 8mg/kg/day (Albaugh et al.,
2006; Arjona et al., 2004; Choi et al., 2007; Cooper et al., 2005; Fell et al., 2004; Pouzet et al.,
2003), while 20mg olanzapine treatment had no effect on food intake or weight gain (Albaugh et
al., 2006; Pouzet et al., 2003). In order to resemble clinical antipsychotic-induced metabolic
dysfunction, dosage selection for use in an animal model should reflect a clinically-relevant
amount, i.e. the recommended olanzapine dose in humans is 5-20mg/day, or 0.07mg0.31mg/kg/day for the average 65kg individual (Kapur et al., 2003). However, direct dosage
translation between humans and rats based on body weight may be inappropriate due to
differences in drug absorption, distribution and metabolism (Kapur et al., 2003). Pharmacokinetic
differences are even noted between rat species (Kapur et al., 2003). A widely accepted measure
of dosage translation is based on clinically comparable dopamine D2 receptor occupancy levels
(Kapur, 1998; Kapur et al., 2003), and calculating differences in body surface area between
species (Reagan-Shaw et al., 2007). Another consideration is treatment administration, which can
alter drug uptake in-vivo, for example, mini-pump administration of olanzapine results in a D2
receptor occupancy of up to 2 times higher than the same dosage administered by subcutaneous
injection (Kapur et al., 2003), and oral gavage can result in more than 2-times higher
concentration of olanzapine in the brain than intra-peritoneal injection (Aravagiri et al., 1999). In
addition, the half-life of olanzapine is approximately 75.2 hours in the human brain (Tauscher et
al., 2002), whereas the drug metabolises at a much faster rate in the rat, i.e. olanzapine has a
half-life of 5.1 hours in the rat brain though high levels remain after 8-hours (Aravagiri et al.,
1999). Therefore, multiple dosages may be required in the rat (8-hourly intervals, three times
daily (t.i.d.) may be required in order to minimise drug fluctuations below sub-therapeutic D2
receptor occupancy levels (Kapur et al., 2003). One method of overcoming inappropriate
oscillations in drug levels may be through the use of a mini-pump (Kapur et al., 2003), however,
issues such as intolerable acidification of solvent in order to achieve the correct drug
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concentration (Kapur et al., 2003) and degradation of olanzapine in solution leading to unstable
levels (van der Zwaal et al., 2008) have been reported, particularly past 14-days’ treatment
(Remington et al., 2011). Other reported treatment administration methods include subcutaneous
or intraperitoneal injection, or oral gavage (Arjona et al., 2004; Fell et al., 2004; Pouzet et al.,
2003), which involve handling and potential injury (de Meijer et al., 2010) and stress on the
animal (Balcombe et al., 2004). A review of 80 studies revealed that physical handling of rats and
mice, including moving their cages, can increase active behaviour (reports range from +190% to
+441%), body temperature (+2.7%), glucose (reports range from +1% to +195%) and growth
hormone (+400%), as well as numerous other parameters, such as heart rate and blood pressure
(Balcombe et al., 2004), that may affect the outcome of studies pertaining to food intake and
weight gain. Oral self-administration through drinking water has been reported (Gao et al., 2005;
Raskind et al., 2006; Shertzer et al., 2010), however maintaining consistent dosing may be
problematic as the majority of antipsychotic drugs are not readily soluble in water, particularly
olanzapine (Eli Lilly and Company Material Data Safety Sheet, Zyprexa Tablets, v1.3,
04/07/2011). Another method of drug delivery is oral self-administration and positive
reinforcement through a palatable reward, eg: chocolate, peanut butter, or cookie-dough (Cope et
al., 2009; Han et al., 2008a; Huang-Brown and Guhad, 2002). Several studies have reported
sensitivity to metabolic side-effects in rats orally self-administered olanzapine in their food (MinetRinguet et al., 2006b; Shobo et al., 2010), even enhanced response compared to gavage or
injection methods (Minet-Ringuet et al., 2006b). A number of other studies have successfully
modelled antipsychotic-induced metabolic side-effects using a cookie-dough administration
method whereby animals learn to eat a sweet-tasting ‘cookie’ containing the required drug
dosage (Albaugh et al., 2006; Albaugh et al., 2010; Deng et al., 2007b; Han et al., 2008a; HuangBrown and Guhad, 2002). The method of oral self-administration mirrors the clinic, is less
invasive than mini-pump implants, and may alleviate handling stress and risk of injury to the
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animal associated with oral gavage and injection. In addition, orally self-administered multiple
dosing in 24 hours may allow a consistently high drug dosage in the rat.

B. Gender Differences
Parts of the following section were published in Weston Green et al., (2010). Sensitivity of the
Female Rat to Olanzapine-Induced Weight Gain – Far from the Clinic?, Schizophrenia Research
116(2-3): 299-300 (Appendix I).

One of the issues overshadowing the ability of the olanzapine-treated animal model to resemble
the clinic is the reported difficulty in replicating olanzapine-induced metabolic dysfunction in the
male rat (Albaugh et al., 2006; Choi et al., 2007; Minet-Ringuet et al., 2006b; Minet-Ringuet et al.,
2005; Pouzet et al., 2003). However, several studies have reported success in modelling
olanzapine-induced metabolic dysfunction in male rats under certain conditions (Hartfield et al.,
2003; Minet-Ringuet et al., 2006a; Ota et al., 2002; Shobo et al., 2010; Thornton-Jones et al.,
2002; van der Zwaal et al., 2010). In addition, a growing body of evidence suggests that female
individuals with schizophrenia are more sensitive to the metabolic side-effects of antipsychotic
drugs than males (Bobes et al., 2003; Hakko et al., 2006; Seeman, 2010; Wu et al., 2007). This
suggests that the sensitivity of the female rat to SGA-induced metabolic dysfunction may not be
as far from the clinic as previously believed.

Based on clinical data, we suggest that the rodent model of olanzapine-induced weight gain
mimics aspects of the human situation as studies have revealed gender-related differences in the
human response to olanzapine treatment. Evidence shows that females with a psychotic disorder
have a 3.6-fold increased risk of weight gain than males (Hakko et al., 2006) and previous studies
have identified female gender as a risk factor and predictor for weight gain associated with
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olanzapine and other atypical antipsychotics (Gebhardt et al., 2009). In fact, Wu et al. (2007)
reported that female first-episode schizophrenia patients had a higher hip to waist ratio, increased
insulin-resistance and higher plasma triglycerides than males following treatment with olanzapine
and clozapine. Kluge et al. (2009) found that olanzapine significantly increased the BMI of female
patients after 1 week of treatment, however male patients took longer to reach significance, and
females exhibited increased skin-fold thickness but not males. Females also showed a 2–4 times
higher level of plasma leptin than males following olanzapine treatment, and this increase was
observed earlier in females than in male patients (Kluge et al., 2009). Furthermore, female
schizophrenia patients are more responsive to olanzapine treatment than male patients,
regardless of illness chronicity (Usall et al., 2007). Female patients also exhibit higher plasma
concentrations of the drug than males (Kelly et al., 1999), possibly due to their generally lower
lean body mass and increased adipose tissue, allowing greater drug storage and leading to
higher plasma levels over time (Yonkers et al., 1992). Gonadal steroids such as oestrogen,
progesterone and testosterone can influence food intake and metabolism. Fitzgerald et al. (2003)
identified significant positive correlations between changes in oestrogen levels and alterations in
leptin and NPY levels as well as BMI and weight gain in female schizophrenia patients treated
with olanzapine or risperidone. These results suggested that fluctuating gonadal steroid levels
may play a role in the weight gain side-effect of atypical antipsychotic drugs and may explain the
higher sensitivity of females to antipsychotic-induced weight gain, though the exact mechanism is
unknown (Fitzgerald et al., 2003). Finally, based on waist circumference measurements,
olanzapine-treated male patients are more responsive to nutritional intervention than females
(Skouroliakou et al., 2009). Indeed, human studies have shown that atypical antipsychoticinduced weight gain does not occur in all patients, and findings from the large-scale Clinical
Antipsychotic Trials of Intervention Effectiveness study showed an increase of 7% weight gain
from baseline in 30% of patients treated with olanzapine (Allison et al., 2009). Taken together, the
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rodent model olanzapine-induced weight gain cannot completely replicate the human weight gain
side-effect, particularly in male rats. However, the sensitivity of female rodents to this side-effect
over males appears to be a common observation in the clinic. Future studies on sex differences
in the rodent model may improve our understanding of the mechanisms underlying gender
response to antipsychotic effects.

C. Overall Comments on Animal Models of Antipsychotic-Induced Weight Gain
Overall, modelling metabolic dysfunction in rats is sensitive to the antipsychotic studied, dosage,
treatment interval, method of administration, and gender of the animal. Olanzapine-induced
metabolic dysfunction can be modelled in female rats; however the most appropriate dosage that
best mimics human metabolic dysfunction side-effects is unclear. Voluntary oral selfadministration resembles the clinic and may reduce animal stress associated with handling.
Based on the half-life of olanzapine, 8-hourly drug treatment intervals are required in order to
maintain appropriate drug levels in the brain. Female rats appear to be more sensitive to
antipsychotic-induced weight gain, which does resemble reports from the clinic (Bobes et al.,
2003; Seeman, 2010).

An appropriate animal model of olanzapine-induced metabolic dysfunction will allow examination
of drug-induced metabolic changes, including investigation of central mechanisms in-vivo that
cannot be explored in humans. In addition, a reliable animal model of olanzapine-induced
metabolic dysfunction is essential for the pre-clinical development of therapeutic interventions
aimed at attenuating or preventing metabolic side-effects.

Katrina Green

42

1.3

AIMS

1.3.1 General Aim

To examine the molecular effects of olanzapine, a second-generation atypical antipsychotic drug
with a high metabolic liability, on key neurotransmitter signalling systems in the hypothalamus
and brainstem, in order to elucidate the mechanisms underlying olanzapine-induced metabolic
side-effects.

1.3.2 Specific Aims

The specific aims of this research were to:
1. Validate a clinically-relevant animal model of olanzapine-induced metabolic dysfunction by
examining drug dosage effects on body weight, food and water intake, subcutaneous and
visceral adiposity, locomotor activity and circulating metabolic hormones insulin, ghrelin, CCK
and PYY(3-36) in the female rat after sub-chronic (14-days) treatment;
2. Investigate the dosage effects of olanzapine on muscarinic M3R binding density in the
hypothalamus and brainstem, and examine the relationship between M3R binding density
and body weight, food intake, plasma insulin, ghrelin, CCK and glucose;
3. Investigate the dosage effects of olanzapine on POMC and NPY mRNA expression,
cannabinoid CB1R binding density, and GABA synthesis (via GAD mRNA expression) in the
hypothalamus and brainstem, and to examine their relationship to body weight gain and
visceral adiposity
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1.3.3 Hypotheses

1. Similar to reports in the clinic, olanzapine will induce body weight gain, accompanied by
hyperphagia, increased adiposity, reduced locomotor activity and metabolic hormone
alterations in the female rat
2. Based on the binding profile of olanzapine, the M3R will be effected by drug treatment and
these alterations will correlate to metabolic dysfunction side-effects
3. Olanzapine will alter POMC and NPY mRNA expression, cannabinoid CB1R binding density,
and GAD mRNA expression and these changes will correlate to body weight and visceral
adiposity.
4. There will be a dose-sensitive response in the parameters measured in the present study,
with a general trend for amplified response with increased dosage within the dosage range
tested.

1.3.4 Significance

Despite significant improvements over the past 60 years in psychopharmacological therapies for
the treatment of schizophrenia and other psychotic illnesses, some widely prescribed
antipsychotics are still associated with intolerable side-effects, including obesity and type II
diabetes mellitus. Antipsychotic-induced metabolic side-effects are particularly concerning due to
associated co-morbidities, including cardiovascular disease and stroke, and patient noncompliance. In addition, the incidence of obesity and diabetes is 1.5-2.0 times higher in
individuals with schizophrenia than the general population, highlighting the urgency of discovering
new drug strategies with high efficacy and low risk of adverse side-effects. In order to assist the
development of new antipsychotics with low metabolic liability, an understanding of the
mechanisms underlying antipsychotic-induced metabolic dysfunction is required. Reports over the
past decade have offered a number of hypotheses on the mechanisms of antipsychotic-induced
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metabolic side-effects, however the answer remains unclear. Indeed, based on the broad
receptor binding profile, it is likely that a number of metabolic alterations may combine to manifest
antipsychotic metabolic side-effects.

Exploring the effects of olanzapine, a high metabolic risk antipsychotic drug, on candidate
neurotransmitter signalling systems in regions of the brain that regulate energy homeostasis will
provide novel understanding of the mechanisms underlying the metabolic side-effects. Results
from the present study may provide direction that can underpin the design and facilitation of
clinical trials aimed at improving antipsychotic-induced metabolic dysfunction in order to enhance
patient outcomes and restore quality of life. In addition, validation of a clinically-relevant animal
model of olanzapine-induced metabolic dysfunction will allow in-vivo investigation of these sideeffects and assist the experimental design of future animal model studies, particularly with
respect to olanzapine dosage selection.
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1.4 GENERAL METHODS
1.4.1 Ethics Statement

This study was approved by the Animal Ethics Committee, University of Wollongong (Application
Approval #: AE06/32), and complied with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (2004), which is in accordance with the International Guiding
Principles for Biomedical Research Involving Animals. All efforts were made to minimise animal
stress and prevent suffering.

1.4.2 Animals and

Drug Treatment

Sixty female adult (7 week old) Sprague Dawley rats were obtained from the Animal Resource
Centre (Perth, WA, Australia) and were housed individually under a 12-hour light-dark cycle
(photophase: 07.00h) at 22OC, with ad libitum access to water and standard laboratory chow (3.9
kcal/g; 10% fat, 74% carbohydrate, 16% protein) throughout the study. Upon arrival, animals
were randomly assigned to 0.25mg/kg, 0.5mg/kg, 1.0mg/kg or 2.0mg/kg olanzapine treatment
groups, or the control group (n=12/group). Animals were habituated for 1 week, then underwent a
teaching period of 1-week where they were taught to self-administer a sweet cookie-dough pellet
offered by metal spoon and were sham-weighed to minimise handling stress during the treatment
period. Methods of olanzapine treatment via cookie dough self-administration were modified from
Huang-Brown and Guad (2002), as previously described by our laboratory (Han et al., 2008a;
Han et al., 2008b; Huang et al., 2006a). Briefly, dry ingredients containing cornstarch (30.9%),
sucrose (30.9%), gelatine (6.3%), casein (15.5%), fibre (6.4%), minerals (8.4%) and vitamins
(1.6%) (62% carbohydrate, 22% protein, 6% fibre, 10% vitamins and minerals) were mixed.
Olanzapine tablets were pulverised using a mortar and pestle following removal of tablet coating.
The calculated dosage of powdered olanzapine was added to weighed dry ingredients and
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enough drops of distilled water were added to achieve a dry dough consistency, immediately prior
to administration. Animals were treated with 0.3g cookie-dough pellets with the assigned
olanzapine dosage (or control) offered by metal spoon three-times daily (t.i.d.) at 8-hourly
intervals for 14 days. Consumption of each pellet was observed to ensure successful dosing.
Body weight, and food and water intake (corrected for spillage) were measured daily.

1.4.3 Behavioural Analysis: Open

Field Testing

Animals were subjected to open field behavioural testing on treatment days 8-10. Methods were
employed as previously described by our laboratory (du Bois et al., 2008). A single animal was
placed in the centre of a 60 cm x 60 cm wide black square arena with 40 cm high walls exposed
to a light intensity of 100 lux. Animal behaviour (distance travelled, velocity, rearing frequency,
and central and peripheral duration) was recorded for 30-minutes and analysed using Ethovision
video-tracking software (Nodulus Information Technology, Wageningen, The Netherlands) (Figure
1.4).

1.4.4 Hormonal and

Adipose Measurements

Following 4-6 hours fasting, animals were euthanized 10-12 hours from the last drug treatment
using sodium pentobarbitone. Blood was removed from the left ventricle. Blood samples for each
hormone were separately collected in tubes containing 2Na-EDTA, aprotinin, K3EDTA or heparin
and immediately centrifuged. Plasma was aliquoted and stored at -20oC. Commercially available
radioimmunoassay (RIA) kits were used to measure plasma CCK, PYY(3-36) (Phoenix
Pharmaceuticals, CA, USA) and total ghrelin (Linco Research, MI, USA), while insulin was
detected using enzyme-linked immunosorbent assay (ELISA) kits (see Chapters 2 and 3 for
details). Adiposity was measured by individually dissecting and weighing inguinal, perirenal and
periovary white fat pads, and sub-scapula brown fat pads.
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Figure 1.4: Example of Open-Field Testing and Ethovision Trace
An example of open-field testing used to examine locomotor activity in a female Sprague Dawley
rat. Animal was placed in the centre of a 60 cm x 60 cm wide black square arena with 40cm high
walls exposed to a light intensity of 100 lux. Locomotor activity (i.e. distance travelled, velocity,
reading frequency, and central and peripheral duration) was recorded for 30-minutes. The red line
is a trace of the animal’s movement, analysed using Ethovision video-tracking software (Nodulus
Information Technology, Wageningen, The Netherlands).
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1.4.5 Histology

Brain tissue was immediately removed following euthanasia, frozen in liquid nitrogen then stored
at -20oC. Six brains were randomly selected from each treatment group and cryostatically
sectioned (14μm, -18oC) along the coronal plane at the levels of Bregma incorporating the
hypothalamus and the DVC (Paxinos and Watson, 2007) (Figure 1.5). Sections were thawmounted onto PolysineTM Microscope Slides (Menzel GmbH & Co. KG, Braunschweig, Germany)
and stored at -20OC.

1.4.6 Receptor Binding

Muscarinic M3 and cannabinoid CB1 receptor binding density experiments were performed using
methods detailed in Chapters 3 and 4, respectively. Radiographic images were captured using a
Beta Imager camera (BioSpace, Paris, France). Radioactivity levels were counted from the
amount of β-particles emitted from the brain sections for 3.5 hours. A slide containing sections
with a known amount of tritium [3H] was used to construct a standard curve. β-Imager Plus
software (version 4, BioSpace) was used to quantify radioactive levels in the hypothalamic Arc
and VMH, and the DVC of the brainstem. The position of the nuclei of interest were confirmed
using a set of cresyl violet-stained slides and a rat brain atlas (Paxinos and Watson, 2007).
Radioligand binding density measurements were converted form nCi/mg tissue to fmol/mg tissue
equivalent using the aforementioned standards.

Katrina Green

49

A. Bregma -2.40mm

B. Bregma -13.68mm

DVC
VMH

Arc

Figure 1.5: Schematic of the rat brain
Depicts the levels of Bregma (A) -2.40mm, incorporating the hypothalamic ventromedial nucleus
(VMH) and arcuate nucleus (Arc); (B) -13.68mm, incorporating the dorsal vagal complex of the
caudal brainstem. Modified from Paxinos and Watson (2007). The Rat Brain. 6th Ed. Academic
Press Inc, USA.
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1.4.7 In-situ Hybridisation

POMC, GAD65 and NPY mRNA expression methodology is described in Chapters 3 and 4.
Expression of mRNA was performed by terminally labelling specific antisense hybridisation
probes with [35S]dATP (1000 Ci/mmol, Perkin Elmer, Waltham, MA, USA) in 10-fold molar
excess, and terminal transferase (Promega, Madison, WI, USA). Labelled probes were purified
using a MicroSpin G-50 column (GE Healthcare Ltd, Buckinghamshire, UK). Slides were
incubated in hybridisation buffer containing 4×SSC, 1×Denhardt’s solution, 50% de-ionised
formamide, 200 μg/ml sperm DNA, 100 μg/1 ml polyA, 120 μg /ml heparin, 20 mM sodium
phosphate and labelled probe (18-hours, 37OC, pH 7.0). Slides were washed in 1x SSC buffer (3
x 30-minutes, 55OC) and incubated in SSC buffer (1-hour, room temperature). Sections were
sequentially dipped in Milli-Q water, 70% then 95% ethanol, and dried under a gentle stream of
air. Autoradiographic images were captured on film (Kodak BioMax MR film, Rochester, NY,
USA). Following exposure for 3 weeks, films were developed using standard procedures. Slides
containing sections with positive signals were then dipped in Emulsion solution (GE Healthcare
Ltd, Buckinghamshire, UK), and exposed for a further 6 weeks. Emulsified slides were stained
using cresyl violet for further identification of positive signals at a cellular level.

Films were analysed using a computer-assisted image analysis system, Quantity One (v4.6.7,
Bio-Rad Laboratories, Inc, CA, USA), connected to a GS-800 Densitometer (Bio-Rad
Laboratories, Inc). Autoradiographic standards containing a known amount of radioactive carbon
[14C] (GE Healthcare Ltd, Buckinghamshire, UK) were used to generate a standard curve.

1.4.8 Statistical Analysis

Power calculation analysis during experimental design revealed a power of 80-85% (JMP 5.1,
SAS Institute Inc., USA), based on studies by Arjona et al. (2004) and Huang et al. (2006a). For a
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power of 80%, 12 animals per group were required to examine body weight, food intake and
behaviour, whereas 6 animals per group were required for neurochemical analysis, in order for
results to be significantly different at an alpha level of 0.05.

All remaining statistical analysis was performed using SPSS (Chicago, IL, USA, version 17.0).
Data points that were outside ±2 standard deviations from the mean were excluded from
analysis. Data was tested for normal distribution using Kolmogorov-Smirnov Tests. Two-way
repeated analysis of variance (ANOVA) tests were employed (‘dosage’ x ‘time’ (days) as a
repeated factor) to examine body weight, food and water intake. Plasma hormones levels,
adiposity, behavioural data, receptor binding density and in-situ hybridisation data were analysed
using one-way ANOVAs. Post-hoc analysis was performed using Dunnett-T tests (when
comparing treatment groups against the control) or Tukey HSD tests (when comparing treatment
groups against the control and other treatment groups). A non-parametric Kruskall-Wallis test was
followed by Mann-Whittney U post-hoc analysis in order to analyse total ghrelin. Throughout the
present study, correlations were observed using Pearson’s correlation tests, or Spearman’s tests
for non-parametric data. Data is expressed as mean ± S.E.M. A p-value less than 0.05 was
considered statistically significant.
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1.5 THESIS SUMMARY

The mechanisms underlying olanzapine-induced metabolic dysfunction in humans remain
unclear. Clinical studies have shown that antipsychotic treatment can interfere with the levels of
circulating metabolic hormones, such as ghrelin and insulin; however the results are conflicting.
Circulating metabolic hormones exert their effects on the brain, particularly the hypothalamus and
caudal brainstem, to signal the energy status of the body. The literature has revealed the
importance of the muscarinic, melanocortinergic, GABA and cannabinoid neurotransmission
systems in regulating appetite, glycaemia and body weight. Alterations to these neurotransmitter
signalling systems during olanzapine treatment may favour a positive energy state and contribute
to body weight gain and insulin dysregulation side-effects. However, studies on the effects of
olanzapine on each of these systems in the hypothalamus and brainstem are limited or lacking.
The ability to examine alterations to neurotransmitter signals during olanzapine treatment is
limited in the human in-vivo. Olanzapine-induced metabolic dysfunction can be modelled in the
rat; however the appropriate dose to use is unclear. Therefore, it is necessary to validate a
clinically comparable animal model of olanzapine-induced metabolic side-effects and identify the
minimum dosage threshold required to change the above-mentioned parameters.

The main findings of the present thesis are summarised in Table 5.1, page 94. Summary
abstracts from each study are shown in the following Sections (1.5.1- 1.5.3).
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1.5.1

Olanzapine Treatment and Metabolic Dysfunction: A Dose Response

Study in Female Sprague Dawley Rats

SGAs are commonly prescribed for the treatment of schizophrenia, however some can induce
metabolic dysfunction side-effects such as weight gain, obesity and diabetes. Clinical reports
suggest olanzapine alters satiety signals, although findings appear conflicting. Previous animal
model studies have utilised a range of olanzapine dosages, however the dosage that better
mimics the human scenario of olanzapine-induced weight gain is unclear. Female Sprague
Dawley rats were treated orally, three times daily with olanzapine (0.25 mg/kg, 0.5 mg/kg, 1.0
mg/kg, 2.0 mg/kg), self-administered in a sweet cookie dough pellet at eight-hourly intervals) or
vehicle (n=12/group) for 14 days. Olanzapine orally self-administered in multiple doses (eighthourly intervals) may circumvent a drop in plasma drug concentration and ensure the
maintenance of a consistently high olanzapine level in the rat. Olanzapine increased body weight
(0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg), food intake (2.0 mg/kg) and feeding efficiency (0.5–2.0
mg/kg), with no effect on water intake. Subcutaneous inguinal (1.0 mg/kg, 2.0 mg/kg) and intraabdominal perirenal fat were increased (2.0 mg/kg), but not interscapula brown adipose tissue.
Olanzapine increased circulating ghrelin and cholecystokinin, but had no effect on peptide YY(3–
36).

Olanzapine decreased insulin (0.25–2.0mg/kg) and locomotor activity in the open field arena

(0.5–2.0 mg/kg). A low dosage of 0.25 mg/kg olanzapine had no effect on most parameters
measured. Olanzapine-induced weight gain is associated with hyperphagia, enhanced feeding
efficiency and adiposity, decreased locomotor activity and altered satiety signalling. The animal
model used in the present study of self-administered oral olanzapine treatment (t.i.d.) at a dosage
range of 0.5–2.0 mg/kg (but not 0.25 mg/kg) mimics aspects of the clinic.
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1.5.2

Effects of olanzapine on muscarinic M3 receptor binding density in the

brain relates to weight gain, plasma insulin and metabolic hormone levels

Cholinergic muscarinic M3 receptors (M3R) are expressed on pancreatic β-cells and in the brain
where they influence insulin secretion and may regulate other metabolic hormones via vagal
innervation of the gastrointestinal tract. Olanzapine's M3R antagonism is an important risk factor
for its diabetogenic liability. However, the effects of olanzapine on central M3Rs are unknown.
Rats were treated with 0.25, 0.5, 1.0 or 2.0 mg olanzapine/kg or vehicle (3x/day, 14 days). M3R
binding densities in the hypothalamic arcuate (Arc) and ventromedial nuclei (VMH), and dorsal
vagal complex (DVC) of the brainstem were investigated using [3H]4-DAMP plus pirenzepine and
AF-DX116. M3R binding correlations to body weight, food intake, insulin, ghrelin and
cholecystokinin (CCK) were analysed. Olanzapine increased M3R binding density in the Arc,
VMH and DVC, body weight, food intake, circulating plasma ghrelin and CCK levels, and
decreased plasma insulin and glucose. M3R negatively correlated to insulin, and positively
correlated to ghrelin, CCK, food intake and body weight. Increased M3R density is a
compensatory up-regulation in response to olanzapine's M3R antagonism. Olanzapine acts on
M3R in regions of the brain that control food intake and insulin secretion. Olanzapine's M3R
blockade in the brain may inhibit the acetylcholine pathway for insulin secretion. These findings
support a role for M3Rs in the modulation of insulin, ghrelin and CCK via the vagus nerve and
provide a mechanism for olanzapine's diabetogenic and weight gain liability.
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1.5.3

Alterations to Melanocortinergic, GABAergic and Cannabinoid

Neurotransmission Associated with Olanzapine-Induced Weight Gain

This study examined the effects of low to high doses of olanzapine on appetite/metabolic
regulatory signals in the hypothalamus and brainstem to elucidate the mechanisms underlying
olanzapine-induced obesity. Levels of pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and
glutamic acid decarboxylase (GAD65, enzyme for GABA synthesis) mRNA expression, and
cannabinoid CB1 receptor (CB1R) binding density (using [3H]SR-141716A) were examined in the
arcuate nucleus (Arc) and dorsal vagal complex (DVC) of female Sprague Dawley rats following
0.25, 0.5, 1.0 or 2.0mg/kg olanzapine or vehicle (3x/day, 14 days). Consistent with its weight gain
liability, olanzapine significantly decreased anorexigenic POMC and increased orexigenic NPY
mRNA expression in a dose-sensitive manner in the Arc. GAD65 mRNA expression increased and
CB1R binding density decreased in the Arc and DVC. Alterations to neurotransmission signals in
the brain significantly correlated with body weight and adiposity. The minimum dosage threshold
required to induce weight gain in the rat was 0.5mg/kg olanzapine. Olanzapine-induced weight
gain is associated with reduced appetite-inhibiting POMC and increased NPY. This study also
supports a role for the CB1R and GABA in the mechanisms underlying weight gain side-effects,
possibly by altering POMC transmission. Metabolic dysfunction can be modelled in the female rat
using low, clinically-comparable olanzapine doses when administered in line with the half-life of
the drug.
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1.5.4 Summary Conclusion

In conclusion, numerous aspects of clinically-reported metabolic dysfunction side-effects can be
modelled in the female Sprague Dawley rat following 14 days’ olanzapine treatment (t.i.d.).
Olanzapine treatment alters a number of neurotransmission signalling systems in regions of the
brain that regulate appetite and metabolism. These changes occur in a manner that can favour
positive energy balance and may contribute to the metabolic dysfunction side-effects of
olanzapine. Results of the present studies suggest that disruption to M3R signalling may underlie
its diabetogenic liability and contribute in part to its weight gain side-effects. Changes to
components of melanocortinergic, GABAergic and cannabinoid neurotransmission in the
hypothalamus and brainstem during olanzapine treatment may contribute to the mechanisms
underlying its obesogenic liability.

The importance of olanzapine dosage has been illustrated in the present series of studies, with a
significant response observed in most parameters following 1.0 or 2.0mg/kg olanzapine (t.i.d.),
but inconsistently following 0.5mg/kg olanzapine, while 0.25mg/kg olanzapine was insufficient to
induce changes in most aspects examined. These findings demonstrate that when administered
in accordance with the half-life of olanzapine in the rat (8-hourly), metabolic dysfunction can be
modelled in the female rat using lower dosages that may better reflect the clinical scenario.
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CHAPTER TWO
OLANZAPINE TREATMENT AND METABOLIC DYSFUNCTION: A DOSE
RESPONSE STUDY IN FEMALE SPRAGUE DAWLEY RATS

Reprinted from Behavioural Brain Research, 217(2), Weston-Green K, Huang XF and Deng C,
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague
Dawley rats, 337-346, Copyright (2011), with permission from Elsevier.
(Albaugh et al., 2006; Allison et al., 1999; Allison et al., 2009; Arjona et al., 2004; Atmaca et al., 2007; Bachus et al., 1997; Balakrishnan et al., 2009; Balcombe et al., 2004; Batterham et al., 2003; Beasley et al., 1996; Beinfeld and
Garver, 1991; Berridge and Peciña, 1995; Boyda et al., 2010b; Brown et al., 1999; Burdyga et al., 2004; Bymaster et al., 1999; Chintoh et al., 2008a; Chintoh et al., 2008b; Chiu et al., 2010; Chiu et al., 2006; Choi et al., 2007;
Coccurello et al., 2009; Coccurello et al., 2008; Coccurello and Moles, 2010; Cooper et al., 2005; Cooper et al., 2008a; Cope et al., 2009; de Leon et al., 1994; Deng et al., 2010; Deng et al., 2007b; du Bois et al., 2008; Eder et al.,
2001; Esen-Danaci et al., 2008; Fell et al., 2004; Gebhardt et al., 2009; Goldman and Hussain, 2004; Gothelf et al., 2002; Goudie et al., 2002; Graham et al., 2005; Han et al., 2008a; Haro et al., 2009; Hartfield et al., 2003; Hiejima et
al., 2009; Hosojima et al., 2006; Houseknecht et al., 2006)(Huang et al., 2006a; Huang et al., 2006b; Jin et al., 2008; Johnson et al., 2005; Kalinichev et al., 2005; Kane et al., 1988; Karl et al., 2006; Keefe et al., 2006; Kim et al., 2008;
Kluge et al., 2009; Lee et al., 1991; Minet-Ringuet et al., 2006a; Minet-Ringuet et al., 2006b; Minet-Ringuet et al., 2005; Murashita et al., 2007; Murashita et al., 2005; Nemeroff, 1997; Orr and Davy, 2005; Ota et al., 2002; Patil et al.,
2006; Perez-Iglesias et al., 2008; Popovic et al., 2007; Pouzet et al., 2003; Procyshyn et al., 2004; Reagan-Shaw et al., 2007; Renuka et al., 2004; Reynolds and Kirk, 2010; Ryan et al., 2004; Schleimer et al., 2005; Schwartz et al.,
2000; Sentissi et al., 2008)(Sharpe et al., 2005; Shobo et al., 2010; Shrestha et al., 2009; Smith et al., 2008; Stefanidis et al., 2009; Tanaka et al., 2008; Thornton-Jones et al., 2002; Tulipano et al., 2007; van der Zwaal et al., 2010;
Vidarsdottir et al., 2010; Virgo et al., 1995; Virkkunen et al., 2002; Wang and Huang, 2008; Weston-Green et al., 2010; Weston-Green et al., 2008; Wu et al., 2008; Yang et al., 2007; Zhang et al., 2004; Zipursky et al., 2005; ZwirskaKorczala
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CHAPTER THREE
EFFECTS OF OLANZAPINE ON MUSCARINIC M3 RECEPTOR BINDING DENSITY
IN THE BRAIN RELATES TO WEIGHT GAIN, PLASMA INSULIN AND METABOLIC

HORMONE LEVELS

Reprinted from European Neuropsychopharmacology, 22(5), Weston-Green K, Huang XF, Lian J,
Deng C, Effects of olanzapine on muscarinic M3 receptor binding density in the brain related to
weight gain, plasma insulin and metabolic hormone levels, 364-373, Copyright (2011), with
permission from Elsevier.
(Albaugh et al., 2006; American Diabetes Association et al., 2004; Aravagiri et al., 1999; Balakrishnan et al., 2009; Berthoud, 2008; Bouche et al., 2004; Buijs et al., 2001; Chintoh et al., 2009; Chintoh et al., 2008a; Chintoh et al.,
2008b; Chiu et al., 2010; Chiu et al., 2006; Coccurello et al., 2009; Coccurello and Moles, 2010; Cone et al., 2001; Crook et al., 2001; Das, 2010; Deng et al., 2007b; Duttaroy et al., 2004; Gautam et al., 2010; Gautam et al., 2006a;
Gautam et al., 2006b; Gibbons et al., 2009; Gilon and Henquin, 2001; Han et al., 2008b; Haro et al., 2009; Johnson et al., 2005; Kapur et al., 2003; Kroeze et al., 2003; Lee et al., 2002; Levey et al., 1994; Li et al., 2009; Li et al., 2003;
Liddle, 2000; Verhagen et al.)(Michel et al., 1989; Newcomer, 2005; Ochi et al., 2005; Perez-Iglesias et al., 2008; Ramankutty, 2002; Reagan-Shaw et al., 2007; Renuka et al., 2004; Reynolds and Kirk, 2010; Rohner-Jeanrenaud and
Jeanrenaud, 1980; Ruiz de Azua et al., 2011; Shen and Johnson, 2000; Silvestre and Prous, 2005; Smith et al., 1981; Starrenburg and Bogers, 2009; Tebbe et al., 2001; Terry Jr et al., 2006; Toshinai et al., 2001; Weston-Green et al.,
2011; White et al., 1990; Yamada et al., 2001; Yang et al., 2009; Zavitsanou et al., 2007; Zubieta and Frey, 1993)
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CHAPTER FOUR
ALTERATIONS TO MELANOCORTINERGIC, GABAERGIC AND CANNABINOID
NEUROTRANSMISSION ASSOCIATED WITH OLANZAPINE-INDUCED WEIGHT
GAIN

Reprinted from PLoS One, 7(3): e33548, Weston-Green K, Huang XF and Deng C, Alterations to
melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapineinduced weight gain, Copyright (2012) Weston-Green et al. under the Creative Commons
Attribution License.
(28 January 2000; Akbarian and Huang, 2006; Albaugh et al., 2006; Alger, 2002; Allison et al., 2009; Aravagiri et al., 1999; Archie et al., 2003; Balcombe et al., 2004; Ballard et al., 2006; Baptista et al., 2002;
Beasley et al., 1996; Beck, 2006; Beck et al., 1992; Bermudez-Silva et al., 2010; Berrendero et al., 1998; Brambilla et al., 2007; Broberger and Hökfelt, 2001; Bronstein et al., 1992; Brown et al., 1999; Budman et
al., 2001; Bymaster et al., 1996a; Bymaster et al., 1996b; Cavuoto and Wittert, 2009; Coccurello and Moles, 2010; Cone, 2005; Cope et al., 2005; Cota et al., 2003b; Cowley et al., 2001; Csiffa´ry et al., 1990;
Davoodi et al., 2009; De Hert et al., 2011; Deng et al., 2007a; Deng et al., 2010; Deng et al., 2007b; Derbenev et al., 2004; Di Marzo et al., 2001; Eder et al., 2001; Erickson et al., 1996; Esclapez et al., 1994;
Faulconbridge et al., 2008; Feldblum et al., 1993; Ferno et al., 2011; Frenchman, 2005)(Gamber et al., 2005; Gomez et al., 2002; Gothelf et al., 2002; Gropp et al., 2005; Guan et al., 1998; Han et al., 2008a;
Harrold and Williams, 2003; Hartfield et al., 2003; Heilig and Murison, 1987; Heilig et al., 1988; Heisler et al., 2002; Hentges et al., 2005; Hentges et al., 2004; Hollopeter et al., 1998; Horvath et al., 1997;
Howlett et al., 2004; Huang et al., 2006a; Huang et al., 2003; Huang et al., 2006b; Kapur et al., 2003; Kapur et al., 2000; Kaufman et al., 1991; Kim et al., 2000; Kim et al., 2007; Kirk et al., 2009; Kirk et al.,
2006; Kirkham, 2008; Kirkham, 2009; Kroeze et al., 2003; Krude et al., 1998; Kuo, 2002; Kuo, 2006; Li et al., 2011; Lin et al., 2004; Lin et al., 2000; Ling et al., 2005; Martin and Rimvall, 1993; Martin et al.,
2004; Meister et al., 2006; Menzies et al., 2010; Minet-Ringuet et al., 2005; Nasrallah, 2003; Nasrallah, 2008; Nemeroff, 1997)(Newcomer, 2005; Nguyen and Wagner, 2007; Nogueiras et al., 2009; Obuchowicz,
1996; Obuchowicz et al., 2004; Obuchowicz et al., 2005; Obuchowicz and Turchan, 1998; Obuchowicz and Turchan, 1999; Ota et al., 2002; Paxinos and Watson, 2007; Pelletier and Simard, 1991; Pertwee, 1997;
Pickar et al., 2008; Pouzet et al., 2003; Qian et al., 2002; Qiu et al., 2007; Rader, 2007; Reagan-Shaw et al., 2007; Remington et al., 2011; Reynolds and Kirk, 2010; Richelson and Souder, 2000; Roseberry et al.,
2004; Roth et al., 2000; Ryan et al., 2004; Schwartz et al., 2000; Secher et al., 2010; Sharkey and Pittman, 2005; Stanley et al., 1986; Starrenburg and Bogers, 2009; Ste Marie et al., 2005; Tauscher et al., 2002;
Tiwari et al., 2010b; Tong et al., 2008; van der Zwaal et al., 2008; Van Sickle et al., 2005; Vong et al., 2011; Weiden et al., 2004; Weston-Green et al., 2011; Weston-Green et al., 2008; Wilson and Nicoll, 2002;
Wu and Palmiter, 2011; Xu et al., 1999; Yoshimatsu, 2006; Zhang et al., 2010; Zhang et al., 2004)
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CHAPTER FIVE
5.1 OVERALL DISCUSSION AND CONCLUSIONS
The present series of studies demonstrate that olanzapine-induced metabolic side-effects are
associated with alterations to muscarinic, melanocortinergic, GABAergic and cannabinoid
neurotransmitter systems in the hypothalamus and brainstem. In addition, these studies show
that multiple aspects of clinically-reported metabolic dysfunction during olanzapine treatment can
be modelled in the female rat and occur in a largely dose-sensitive manner. Overall, these studies
indicate that disruption to neurotransmitter signalling pathways involved in regulating appetite,
glucose homeostasis and body weight may underlie a shift in energy balance that favours weight
gain and insulin dysregulation during olanzapine treatment. Changes in the parameters examined
occurred within 14 days’ treatment, when a sharp increase in body weight is observed in the rat
(Han et al., 2008a; Huang et al., 2006a). These findings contribute novel data towards
understanding the mechanisms underlying olanzapine-induced metabolic side-effects and provide
direction on optimal dosage for future animal modelling studies. This chapter will provide a
general discussion of the findings and the potential mechanisms for olanzapine-induced
metabolic dysfunction based on interactions between the systems examined (illustrated in Figure
5.1, pages 99-100). A detailed discussion of each study has been included at the end of Chapters
2-4. The main findings of this thesis are summarised in Table 5.1.

5.1.1 The Mechanisms of Olanzapine-Induced

Metabolic Dysfunction

In Chapter 2 it was found that olanzapine self-administered in a sweet cookie dough pellet at 8hourly intervals (t.i.d.) for 14 days induced metabolic side-effects in female Sprague Dawley rats
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Table 5.1: Summary of Main Findings in Chapters 2-4
Olanzapine Dosage Effect
Parameter
Total Body Weight Gained (g)
Consumption
Food Intake (g)
Feeding Efficiency#
Water Intake (ml)
Adiposity (Fat Mass, g)
Inguinal
Perirenal
Periovary
Total White Fat
Subscapular Brown Fat
Plasma Hormone Levels (fmoles/ml)
Insulin
Total Ghrelin
Cholecystokinin
Peptide YY(3-36)
Behaviour – Open Field
Total Distance Travelled (cm)
Mean Velocity (cm/s)
Rearing Frequency
Centre Duration (s)
Periphery Duration (s)
Centre Frequency
Periphery Frequency
M3R Binding Density (fmoles/mg tissue)
Arcuate Nucleus
Ventromedial Hypothalamic Nuclei
Dorsal Vagal Complex
POMC mRNA Expression (nCi/g tissue)
Arcuate Nucleus
Dorsal Vagal Complex
GAD65 mRNA Expression (nCi/g tissue)
Arcuate Nucleus
Dorsal Vagal Complex
CB1R Binding Density (fmoles/mg tissue)
Arcuate Nucleus
Dorsal Vagal Complex
NPY mRNA Expression (nCi/g tissue)
Arcuate Nucleus
Ventromedial Hypothalamic Nuclei
Dorsal Vagal Complex

0.25mg/kg
NSC

0.5mg/kg
*

1.0mg/kg
*

2.0mg/kg
**

NSC
NSC
NSC

NSC
*
NSC

NSC
**
NSC

**
**
NSC

NSC
NSC
NSC
NSC
NSC

NSC
NSC
NSC
NSC
NSC

**
NSC
NSC
**
NSC

**
*
NSC
**
NSC

**
*
NSC
NSC

**
**
**
NSC

**
*
NSC
NSC

**
*
**
NSC

NSC
NSC
NSC
NSC
NSC
NSC
NSC

*
**
*
NSC
NSC
NSC
NSC

**
**
**
**
**
**
**

**^
**
**
**
**
**
**

 (t)
*
NSC

**
**
*

**
**
**

**
**
**

NSC
NSC

**
NSC

**
NSC

**
NSC

NSC
NSC

NSC
NSC

*
**

**
**

**
NSC

**
*

**
*

**
*

NSC
NSC
NSC

NSC
NSC
NSC

**
NSC
NSC

**
NSC
NSC

Abbreviations: CB1R: cannabinoid CB1 receptor, GAD65: glutamic acid decarboxylase isoform 65,
M3R: muscarinic M3 receptor, NSC: no significant change, NPY: neuropeptide Y, POMC: proopiomelanocortin. #(g weight gained / g food intake), *p<0.05 vs. control, **p<0.01 vs. control,
t=trend, p=0.053.
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including weight gain, hyperphagia, enhanced feeding efficiency, increased intra-abdominal and
subcutaneous adiposity, and decreased gross motor activity in an open-field paradigm.
Olanzapine also altered circulating plasma metabolic hormones, i.e. decreased insulin, increased
ghrelin and CCK levels, but had no effect on PYY(3-36) levels. These findings demonstrate that
metabolic side-effects induced by olanzapine can be modelled in the rat in a manner that is
consistent with reports from the clinic (Alvarez-Jimenez et al., 2006; Brown et al., 1999; Chiu et
al., 2006; Eder et al., 2001; Gothelf et al., 2002; Murashita et al., 2007; Nemeroff, 1997; Ryan et
al., 2004; Vidarsdottir et al., 2010), and validate this animal model as a solid foundation to
investigate the effects of olanzapine on key candidate neurotransmission systems in the brain, invivo, in order to understand the underlying mechanisms of olanzapine-induced metabolic
dysfunction.

As discussed in Chapters 1 and 3, several lines of evidence point to a critical role for the
muscarinic M3R in the production and secretion of insulin via vagal innervation of the pancreas
(Duttaroy et al., 2004; Gautam et al., 2006b; Gautam et al., 2008; Gromada and Hughes, 2006;
Jindal and Keshavan, 2006; Ruiz de Azua et al., 2011). However, olanzapine is a potent
antagonist of the muscarinic M3R (Johnson et al., 2005). In Chapter 3, it was reported for the first
time that olanzapine acts on M3Rs in the hypothalamic VMH and Arc, and the DVC of the caudal
brainstem, resulting in a compensatory increase in M3R binding density in these regions (Figure
5.1). Given the important role of the M3R in facilitating insulin secretion, it is interesting that
alterations in M3R binding density correlated with reduced plasma insulin levels. My findings
support a novel mechanism for olanzapine-induced insulin dysregulation whereby direct blockade
of the M3R by olanzapine in the brainstem and hypothalamus inhibits the vagally-mediated ACh
pathway for insulin secretion. Insulin dysregulation due to M3R blockade by olanzapine during the
sub-chronic phase of treatment may be the initial insult that leads to insulin-resistance and type II
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diabetes mellitus reported in the clinic during chronic treatment (Lambert et al., 2006; Lykkegaard
et al., 2008; Sernyak et al., 2002). Clinical studies have reported the onset of type II diabetes
mellitus in olanzapine-treated individuals that did not experience concurrent gains in body weight
(Lambert et al., 2006; Ramankutty, 2002). Importantly, my data shows that M3R blockade by
olanzapine can be a mechanism for type II diabetes independent of body weight gain as insulin
dysregulation and M3R density changes were observed in the lowest olanzapine dosage group
(0.25mg/kg olanzapine), which did not exhibit significant body weight gain. In addition to insulin
levels, M3R binding density also correlated with plasma ghrelin and CCK levels. Studies have
shown that the vagus nerve exerts inhibitory tone over ghrelin secretion (Lee et al., 2002;
Toshinai et al., 2001) and that ghrelin secretion can be regulated by ACh (Shrestha et al., 2009),
although not through the M1 or M4 receptor sub-types as pirenzepine has no effect on ghrelin
levels (Broglio et al., 2004). In addition, a vagotomy enhances CCK levels in humans (Liddle,
2000), however vagal-cholinergic inhibition attenuates CCK satiation (Smith et al., 1981). My
findings suggest that cholinergic M3R blockade by olanzapine may contribute to an increase in
ghrelin and CCK levels, but inhibits the satiating pathway of CCK, through impaired vagal
cholinergic signalling pathways. Collectively, the results of Chapter 3 show for the first time that
olanzapine’s antagonism of the M3R is associated with altered levels of metabolic hormones that
signal appetite and the body’s nutritional status to the brain, such as ghrelin, insulin and CCK,
possibly through impaired vagal cholinergic signalling pathways to the GI tract (Figure 5.1).

A further novel contribution towards understanding the mechanisms underlying olanzapineinduced weight gain was the identification of changes to POMC/NPY and CB1R/GABA
microcircuitry in the hypothalamus in a manner that favours weight gain during olanzapine
treatment (Chapter 4). Olanzapine reduced anorexigenic POMC and increased orexigenic NPY
mRNA expression in the hypothalamus, while concurrently reducing CB1R binding density and
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enhancing GAD65 mRNA expression in both the hypothalamus and brainstem. An increase in
hypothalamic NPY and reduction in POMC mRNA expression can have profound effects on body
weight through both sides of the energy equation, i.e. increased appetite and reduced activity
(Heilig and Murison, 1987; Huo et al., 2009). Based on my findings, a new mechanism for
olanzapine-induced weight gain involving interactions between local hypothalamic signalling
pathways was proposed, whereby increased NPY and enhanced inhibitory GABAergic output,
possibly through reduced CB1R density, contribute to POMC inhibition (see Figure 4.6, Chapter
4). My results demonstrate that olanzapine acts on a number of neurotransmitter signalling
pathways in regions of the brain that regulate energy homeostasis. But the key question is: how
do changes in hormonal signals interact with neurotransmission pathways, in particular
POMC/NPY, in the hypothalamus and brainstem during olanzapine treatment? A possible link
between peripheral and neural effects during olanzapine treatment is interactions with the M3R
(Figure 5.1), since olanzapine has a very low/no affinity for GABA receptors or CB1Rs (Roth and
Driscol, 2011).

As discussed in Chapter 1, metabolic hormones exert their effects on the brain to convey
information pertaining to the nutritional and energy status of the body, and thus, hypothalamic
neuropeptide expression can be modulated by peripheral metabolic condition (see Section
1.2.3.B. Brain-Gut Axis, page 16). Insulin, ghrelin and CCK mediate their appetite effects, in part,
by regulating NPY and/or POMC. For example, anorexigenic insulin enhances POMC mRNA
expression and inhibits NPY in the Arc through insulin receptors expressed by these neurons
(Plum et al., 2006), whereas expression of the NPY precursor molecule, prepro-NPY, is
increased in the Arc of insulin-deficient streptozotocin-diabetic rats (White et al., 1990). Ghrelin
inhibits POMC by enhancing inhibitory GABA release from NPY terminals (Cowley et al., 2003)
and data from the present studies show a positive correlation between ghrelin and GAD65 mRNA
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expression in both the Arc and DVC (r=0.51, p<0.05 and r=0.57, p<0.01, respectively). CCK
administration selectively activates POMC neurons in the NTS via the vagus nerve (Fan et al.,
2004), however olanzapine did not affect POMC expression in the DVC. During olanzapine
treatment impaired cholinergic signalling, i.e. through M3R blockade, may inhibit the ability of
CCK to activate POMC in the NTS and induce satiety. Taken together, a reduction in insulin and
increase in ghrelin during olanzapine treatment through M3R blockade may contribute to body
weight gain by enhancing NPY and GABAergic inhibitory tone and suppressing POMC (Figure
5.1). Impaired cholinergic signalling pathways during olanzapine treatment may reduce satiety
signalling to the brainstem. Moreover, my data shows that the M3R can indirectly influence
hypothalamic neuropeptides by altering plasma hormone signalling to the brain (Figure 5.1);
indeed, NPY and POMC mRNA expression positively correlated with M3R density in the Arc
(r=0.58, p<0.01 and r=0.51, p<0.01, respectively) in the present study. Figure 5.1 illustrates a
possible mechanism for olanzapine-induced weight gain and insulin dysregulation through
interactions between systems examined in the present series of studies.

In addition to an indirect role for the M3R in olanzapine-induced metabolic dysfunction via
hormone regulation, several studies demonstrate that the M3R plays a direct role in cannabinoid
and GABAergic neurotransmission. A study by Marini et al., (2009) reported that pre-activation of
the M3R in human neuroblastoma SH-SY5Y cells increases intracellular calcium levels up to 8fold compared to CB1R activation alone. The idea that M3Rs work with CB1Rs to modulate
intracellular calcium levels has interesting implications for the vesicular release of GABA and
subsequent regulation of POMC (Figure 5.1). In the hippocampus, M1/M3R activation increases
endogenous cannabinoid production, which suppresses GABA release via CB1R activation
(Fukudome et al., 2004). On the other hand, M3R antagonism by olanzapine may reduce
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Figure 5.1: A Potential Mechanism Underlying Olanzapine-Induced Metabolic Dysfunction Based on this Study
M3R blockade by olanzapine causes a compensatory upregulation of M3R density in the Arc, VMH and DVC (1), and inhibits the ACh-mediated pathway of
insulin secretion (2), causing hypoinsulinaemia (3). Interference in cholinergic vagal innervation of the stomach and intestines (2) causes an increase in
orexigenic ghrelin (4) and anorexigenic CCK (5). Olanzapine increases NPY and GAD65 mRNA expression (6), which inhibit anorexigenic POMC neurons (7).
Activation of GHS-R on NPY neurons (8) contributes to GABAergic inhibition of POMC (7). Hypoinsulinaemia during olanzapine treatment reduces inhibition
of NPY and activation of POMC. Vagal cholinergic inhibition during olanzapine treatment, via M3R blockade, may prevent CCK activation of POMC in the
NTS (9). POMC neurons in the Arc express endogenous cannabinoids, which diffuse in a retrograde manner to activate CB1Rs expressed on GABAergic
neurons (10). Activation of the CB1R stimulates the G-protein coupled βγ subunit to inhibit opening of Ca2+ channels (11), which reduces the probability of
vesicular release of GABA from the axon terminal, disinhibiting POMC. However, olanzapine decreases CB1R density, allowing Ca2+ channels to open and
enhance release of GABA onto the post-synaptic POMC neuron. Increased GABA synthesis during olanzapine treatment would allow greater inhibitory input
to POMC (12). Collectively, olanzapine-induced alterations to insulin, ghrelin and CCK signalling to the brain, through M3R blockade, contributes to altered
local regulation of hypothalamic POMC and NPY by GABAergic and cannabinoid neurotransmission in a manner that suppresses anorexigenic signalling and
favours weight gain during the early stage* of olanzapine treatment. In addition, the M3R can directly interact with GABAergic neurotransmission by
modulating endocannabinoid levels and subsequent activation of the CB1R (13).
Abbreviations: ACh: acetylcholine, Arc: arcuate nucleus, CCK: cholecystokinin, CCK-R: cholecystokinin receptor, DVC: dorsal vagal complex, GABA: γAminobutyric acid, GAD65: glutamic acid decarboxylase isoform 65, GHS-R: growth hormone secretagogue (ghrelin) receptor, IR: insulin receptor, M3R:
muscarinic M3 receptor, NPY: neuropeptide Y, NTS: nucleus of the solitary tract, POMC: pro-opiomelanocortin, VMH: ventromedial hypothalamic nucleus.
Picture modified from Weston-Green et al., PLoS One (Manuscript Accepted 11th February, 2012, In Press).
*Note: Chronic treatment with olanzapine can cause hyperinsulinaemia (discussed in Chapters 1 and 3).
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cannabinoid production and enhance GABA release; however under conditions of low
endogenous ligand, a compensatory increase in CB1R density over time would be expected.

Although olanzapine potently blocks the M3R, the functional outcome of increased M3R density
throughout olanzapine treatment requires further examination. Given the complexity of energy
homeostasis and the broad receptor binding profile of olanzapine, the mechanisms discussed in
this chapter may contribute partially to the metabolic side-effects of olanzapine and more
research is required. As discussed in Chapter 4, olanzapine is a histamine H1 receptor antagonist
(Richelson and Souder, 2000) and antipsychotic affinity for the H1 receptor can predict its weight
gain liability (Kroeze et al., 2003); however, the underlying mechanisms for the effect of the H1
receptor on antipsychotic-induced body weight gain may be independent of melanocortinergic
neurotransmission (Yoshimatsu, 2006). In addition, interactions between the melanocortinergic
system, and receptor sub-types of the dopaminergic and serotonergic neurotransmission systems
have been demonstrated (Heisler et al., 2002; Kuo, 2002; Kuo, 2006; Pelletier and Simard, 1991;
Qiu et al., 2007) and may contribute to olanzapine-induced metabolic side-effects (Kirk et al.,
2009). Also, it is important to note that statistical correlations do not provide direct evidence of a
causal link and further studies are required to confirm the proposed mechanisms contained within
this series of studies. Nevertheless, these results have given some insight into the mechanisms
underlying olanzapine-induced metabolic dysfunction.

5.1.2. Recommendations for Further

Research

Based on the findings of the present series of studies, recommendations for further research are
as follows:
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1. Olanzapine treatment altered the mRNA expression of POMC, NPY and GAD65, however
levels of mRNA expression may not necessarily reflect the amount of protein. Western blot
techniques may be utilised to examine changes on a protein level as well as effects on
downstream pathways in a future study.

2. Olanzapine-induced alterations in CB1Rs and M3Rs were observed using receptor binding
autoradiographic methods. Further studies are required to identify whether these changes
were a result of receptor number or binding affinity, and whether the receptor changes
reflected downstream signalling alterations. Functional binding assays using [35S]GTP-γ-S
binding can determine the function of GPCRs, while western blot techniques can detect
downstream signalling proteins. However, the development of an M3R-specific ligand is
required to accurately examine the binding affinity of the M3R.

3. NPY mRNA expression increased in the present study following 14 days’ olanzapine
treatment, whereas NPY mRNA expression did not change after 5 weeks’ olanzapine
treatment (Huang et al., 2006b). Although the studies differ in experimental design (i.e.
1.2mg/kg olanzapine administered once daily for 5 weeks), these findings may indicate a
time-dependent sensitivity of NPY mRNA expression to olanzapine treatment that resembles
the ‘peak and plateau’ trend observed in body weight gain in humans and rats. Further
studies examining the time-course of NPY mRNA expression during olanzapine treatment will
assist in clarifying this theory.

4. My results revealed hypoinsulinaemia, low blood glucose levels and an increase in M3R
density following 2 weeks’ olanzapine treatment, whereas it is well-documented that chronic
olanzapine treatment is associated with hyperinsulinaemia and hyperglycaemia (Oriot et al.,
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2008; Perez-Iglesias et al., 2008). Interestingly, a clinical study found that olanzapine induced
a time-dependent change in insulin secretion over 8 weeks’ treatment (Chiu et al., 2010).
Therefore, further studies examining the effects of olanzapine on neuronal and pancreatic
M3Rs, as well as insulin and glucose levels at several stages of treatment (acute, subchronic, chronic phases) would be useful. Investigation into glucose tolerance testing and
insulin sensitivity over time should also be conducted.

5. Future development of an M3R-specific agonist may have clinical implications whereby cotreatment with olanzapine may be able to prevent or attenuate the initial insulin dysfunction
induced by M3R blockade. Co-treatment with an M3R agonist may also alleviate imbalances
in other metabolic hormones, such as ghrelin and CCK. Furthermore, several studies have
shown that aspects of gluco-metabolic dysfunction can be modelled in the rat using clozapine
(Murashita et al., 2007; Tulipano et al., 2007). Clozapine is also a potent M3R antagonist
(Johnson et al., 2005) and has the highest diabetogenic/obesogenic liability of all SGAs
(Newcomer, 2005); therefore M3R agonist co-treatment should also be examined in a preclinical model to test clinical viability. Importantly, removal of M3R antagonistic properties in
future SGAs may be beneficial to reduce metabolic side-effects.
6. Male rats exhibit enhanced sensitivity to olanzapine-induced metabolic side-effects when the
drug is self-administered via their food source (Minet-Ringuet et al., 2006a; Shobo et al.,
2010). Therefore, utilising the experimental design employed in Chapter 2, i.e. dosage
considerations, treatment interval and administration method, may be beneficial in enhancing
response in the male rat for the development of a better male rat model.
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5.1.3. Conclusion

The results of the present thesis have demonstrated that alterations to a number of major
metabolic pathways in the brain and periphery contribute to olanzapine’s metabolic side-effects.
An olanzapine dosage response was apparent in most parameters measured (summarised in
Table 5.1, page 94). Olanzapine-induced body weight gain is associated with hyperphagia,
adiposity, altered circulating metabolic hormone levels and decreased locomotor activity.
Olanzapine alters specific neuropeptides and neurotransmitter receptor systems in regions of the
brain that regulate energy homeostasis through food intake and locomotor activity. Olanzapine
increased M3R binding density in the hypothalamus and brainstem, which was likely to be a
homeostatic upregulation due to the drug’s profile to potently block the M3R. Olanzapine’s
antagonism of the M3R may interfere in the cholinergic pathway for GI regulation, contributing in
part to its weight gain side-effects through interference in cholinergic vagal innervation of the GI
tract, resulting in abnormal ghrelin and CCK levels. However, olanzapine’s effects on the M3R
may be more important to its diabetogenic liability through insulin dysregulation and resultant
glucose homeostatic imbalance that precedes insulin-resistance and type II diabetes mellitus.
The present study demonstrates a mechanism for olanzapine-induced insulin dysregulation that
is independent of body weight gain. Olanzapine increases NPY and decreases POMC mRNA
expression in the Arc, which may contribute to body weight gain by increasing appetite and
reducing locomotor activity. In addition, olanzapine decreases CB1R binding density and
increases the GABA synthesising enzyme, GAD65, in the Arc and DVC. These alterations may
interfere in the CB1R-mediated GABAergic inhibition of POMC neurons in the Arc, but through a
different post-synaptic neuron in the DVC. Taken together, numerous aspects of metabolic
dysfunction reported in the clinic during olanzapine treatment can be modelled in the female rat
using clinically comparable drug dosages. This model provides a foundation for the examination
of drug-effects in vivo, in order to understand the mechanisms by which olanzapine induces
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obesity and type II diabetes mellitus side-effects. The present study offers insight into the
mechanisms underlying antipsychotic-induced metabolic side-effects and novel directions for the
design of new generation antipsychotic drugs that have reduced metabolic side-effects in order to
enhance patient outcomes and quality of life.
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APPENDIX ONE

A1.1 SENSITIVITY OF THE FEMALE RAT TO OLANZAPINE-INDUCED WEIGHT

GAIN – FAR FROM THE CLINIC?

Reprinted from Schizophrenia Research, 116(2-3), Weston-Green K, Huang XF and Deng C,
Sensitivity of the Female Rat to olanzapine-induced weight gain – Far from the clinic?, 299-300,
Copyright (2010), with permission from Elsevier.
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